Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Systematic Overview of Warfarin and Its Drug and Food Interactions

Systematic Overview of Warfarin and Its Drug and Food Interactions BackgroundWarfarin is a highly efficacious oral anticoagulant, but its use is limited by a well-founded fear of bleeding. Drug and food interactions are frequently cited as causes of adverse events with warfarin. We provide an updated systematic overview of the quality, clinical effect, and importance of these reported interactions.Data SourcesMEDLINE, TOXLINE, IPA, and EMBASE databases from October 1993 to March 2004. Database searches combined the keyword warfarinwith drug interactions, herbal medicines, Chinese herbal drugs, and food-drug interactions.Study SelectionEligible articles contained original reports of warfarin drug or food interactions in human subjects. Non-English articles were included if sufficient information could be abstracted.Data ExtractionReports were rated independently by 2 investigators for interaction direction, clinical severity, and quality of evidence. Quality of evidence was based on previously validated causation criteria and study design.Data SynthesisOf 642 citations retrieved, 181 eligible articles contained original reports on 120 drugs or foods. Inter-rater agreement was excellent, with weighted κ values of 0.84 to 1.00. Of all reports, 72% described a potentiation of warfarin’s effect and 84% were of poor quality, 86% of which were single case reports. The 31 incidents of clinically significant bleeding were all single case reports. Newly reported interactions included celecoxib, rofecoxib, and herbal substances, such as green tea and danshen.ConclusionsThe number of drugs reported to interact with warfarin continues to expand. While most reports are of poor quality and present potentially misleading conclusions, the consistency of reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil, suggests that coadministration with warfarin should be avoided or closely monitored. More systematic study of warfarin drug interactions in patients is urgently needed.Warfarin is the most commonly used oral anticoagulant in North America and has established efficacy for the prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease.The drug is a racemic mixture of 2 optically active isomers, though the S-enantiomer is approximately 5 times more potent than the R-enantiomer. Warfarin exerts its effect by lowering the amount of active vitamin K available for the activation of clotting factors II, VII, IX, and X.Both effectiveness and safety (primarily risk of bleeding) are related to blood international normalized ratio (INR) values. Monitoring of INR and dose adjustments of warfarin are frequently required, influenced by changes in concomitant medications, diet, alcohol consumption, acute illness, liver disease, and unknown factors.Despite the frequency and importance of warfarin’s drug and food interactions, the first systematic overview on the topic did not appear until 1994.For that review, we developed an interaction assessment tool that combined a “levels of evidence” approach with causation criteria, subject outcome, and proposed mechanisms. Although many drugs, including antibiotics, drugs affecting the central nervous system, and cardiac medications, had been reported to interact with warfarin, the quality of reports was so poor that few clinical recommendations could be made other than careful monitoring around initiating and discontinuing treatment with other medications. In the decade since that review, awareness and investigation of drug interactions and quality of evidence have grown, leading to the hypothesis that the number and quality of drug and food interactions would increase as well. We therefore performed a systematic overview of the literature, updating the evidence on warfarin drug and food interactions.METHODSRelevant literature was identified by searching MEDLINE, TOXLINE, IPA, EMBASE databases, Health Canada and Food and Drug Administration Web sites and personal files from October 1993 to the end of March 2004. The MeSH headings and keywords used for the search were warfarinand drug interactions. Non-English articles were included if they included an English abstract with sufficient information. To retrieve warfarin-herbal drug interactions and warfarin-food interactions, 2 additional searches were conducted using the MeSH headings and keywords warfarinand herbal medicinesor Chinese herbal drugs, and MeSH headings food-drug interactionsand warfarin, limited to English only. The bibliographies of the retrieved articles were checked for any additional pertinent studies. Articles were considered eligible for evaluation if they contained original data involving drug or food interactions with warfarin in human subjects. Interacting drugs had to be available in the United States or Canada. Eligible studies were evaluated independently by 2 authors according to the following 4 main categories.SUBJECTSubjects were classified as patients or healthy volunteers. Patients were then further stratified into 2 categories: volunteers and nonvolunteers. The former group were defined as patients requiring warfarin therapy who were prospectively entered into a study, whereas the latter group was exposed to the interacting drug during the course of usual warfarin therapy. Healthy volunteers were healthy individuals not requiring warfarin therapy.INTERACTION CLASSIFICATION AND SEVERITYThe drug affected and the type of interaction (potentiation, inhibition, or no effect) were noted. Interactions that potentiated or inhibited the effect of warfarin were further rated as major, moderate, minor, or nonclinical.Major potentiation was defined by death, major bleeding, or necessity to stop warfarin therapy entirely. Major bleeding episodes included those that were life-threatening as well as those that led to the loss of at least 2 units of blood in 7 days or less.Moderate potentiation meant that (1) there was an INR change requiring an adjustment in warfarin dosage or (2) the INR increased to greater than 5.0 or (3) there was an increase in INR by greater than 1.5. Minor potentiation interactions were defined as an INR increase in which (1) no change in warfarin dosage was required and (2) the ratio remained less than 5 and (3) the increase was less than 1.5. Potentiation interactions were classified as nonclinical if the only evidence of warfarin augmentation was a statistically significant increase in warfarin levels without change in INR or clinical status.Major inhibition interactions were defined by the occurrence of thrombosis. Moderate inhibition (clinically relevant but less than major) indicated (1) a change in INR requiring an adjustment in warfarin dosage or (2) an INR decrease to less than 1.5 or (3) a decrease in INR by greater than 1.5 units. Minor inhibition interactions were defined by (1) an INR decrease requiring no change in warfarin dosage and (2) an INR decrease to a ratio that remained more than 1.5 and (3) a decrease in INR by less than 1.5. Inhibition interactions were classified as nonclinical if the only evidence of warfarin inhibition was a statistically significant decrease in warfarin levels.An interaction was defined as having no effect if the interacting drug neither potentiated nor inhibited warfarin’s effect in any way described herein.QUALITY OF STUDYReports were classified into 1 of 4 categories based on the quality of study design. As shown in Table 1, randomized controlled trials (RCTs) were subdivided into fair to excellent quality, with those involving more than 100 subjects arbitrarily given the highest rating. Poor quality reports included nonrandomized study designs, observational studies, pharmacokinetic studies, and case reports.Table 1. Quality of Study DesignQualityStudy DesignExcellentRCTs with >100 subjectsGoodRCTs with 20-100 subjectsFairRCTs with <20 subjectsPoor Group 1Observational studies (cohort, case-control) Group 2Case series, case reports, pharmacokinetic studiesAbbreviation: RCTs, randomized controlled trials.CAUSATION CRITERIAFor each report, the probability of the proposed interaction was rated from level I (highly probable) to level IV (highly improbable). Definitive evidence of an interaction required a level I causation rating from both healthy volunteer and patient-based reports in which both described identical interaction direction and severity. Level designation was based on how the article fulfilled 7 standard causation criteria.Level of CausationCausation Criteria RequiredI (Highly probable)A, B, C, and ≥1 of D to GII (Probable)A, B, and ≥1 of C to GIII (Possible)A and ≥1 of B to GIV (Highly improbable)A alone or any combination of B to GIs the timing correct for an interaction to be pharmacologically plausible? In patient-based studies, warfarin must have been taken at a stabilized dose common to usual practice and prior to initiation of the interacting drug or food. For volunteer-based studies, subjects had to have received warfarin, both alone as well as with the interacting drug. In addition, we required that the potentially interacting drug had to be consumed (1) long enough to attain a significant plasma level and (2) in doses common to usual practice.Do laboratory tests (eg, international normalized ratio/prothrombin time/thrombotest) support the contention of an interaction? In patient-based articles, the post-coadministration coagulation variable had to be out of therapeutic range, whereas for volunteer studies, a 20% change in coagulation parameters for volunteer studies was required. For articles concluding “no interaction,” the absence of a statistically significant change in coagulation variables was required.Are other potential factors affecting warfarin pharmacokinetics/pharmacodynamics ruled out satisfactorily? Factors such as diet, other medications, as well as certain medical conditions (hepatic dysfunction and hyperthyroidism) had to have been declared to be ruled out as possible causes of the outcome.Has the patient had a similar result with previous exposure to the same drug? The patient had to have been taking the interacting drug in addition to warfarin at a time prior to that reported with a similar outcome.Was a dose-response relationship demonstrated for the interacting drug? The alterations in the dose of the implicated interacting drug or food being administered with warfarin correlated with subsequent changes in coagulation variables, inferring a dose-response relationship.Was the subject rechallenged and, if so, did a similar response occur? The interacting drug had to have been administered simultaneously with warfarin in 2 or more separate courses (the second course conducted to confirm the results of the first), with similar results each time.Are the authors’ conclusions supported by other objective evidence? Other objective evidence such as plasma levels of warfarin or coagulation factors supported the authors’ conclusions.RELIABILITY AND VALIDITYThe criteria and rating scheme were evaluated and approved a priori by a panel of experts in the fields of thromboembolism, clinical pharmacology, and clinical epidemiology to assure face validity. Interrater agreement for interaction direction and severity, quality of study, and level of causation was assessed using a weighted κ statistic.CONFLICTING EVIDENCEIf ratings differed among articles for the same interacting drug or food, a hierarchy was implemented (type of subject > quality of study > level of causation > severity of clinical outcome). For example, a case report involving a patient was considered to be superior to an RCT using healthy volunteers as subjects. If 2 or more articles had the same subject type, the result of the highest quality study was listed—a patient-based RCT was considered superior to a patient case report. If 2 or more articles with the same subject type and quality of study varied in level of causation and clinical outcome, the clinical outcome associated with the highest level of evidence was listed. For example, the case report describing moderate potentiation of warfarin by celecoxib, with a level II causation ratingoutweighed the level III case report describing a similar interaction.For 2 level III causation patient case reports describing amoxicillin’s effect on warfarin, the report describing major potentiationoutweighed the one describing moderate potentiation.RESULTSA total of 642 citations were identified, of which 205 contained original data on drug or food interactions with warfarin. Of these 205 articles, 181 were retrievable and available for review. The reviewed articles contained 187 separate reports of interactions involving 120 drugs or foods. The weighted κ statistic for the interaction direction and severity rating, level of causation evaluation, and quality of study rating among the reviewers were 0.98, 0.84, and 1.0 respectively. All rating disagreements were resolved by repeated review and consensus.No study met our definition of excellent quality. Thirty-three small RCTs were rated fair or good quality, of which 28 involved healthy subjects and 26 concluded a lack of interaction between warfarin and the drug or food studied. Olestra,vitamin E,clopidogrel,coenzyme Q10/ginkgo biloba 10,and ciprofloxacinwere the only drugs for which patient-based RCTs were conducted, with a “no effect” conclusion for olestra, vitamin E, clopidogrel, and coenzyme Q10/gingko biloba and nonclinical potentiation for ciprofloxacin. Of the reviewed studies, 148 (82%) were rated poor quality and 130 (88%) of these were case reports, of which 125 (96%) were single case reports.Forty-one new reports were rated as level I causation (highly probable) for an interaction, with 14 reporting potentiation (acetaminophen,boldo-fenugreek,ciprofloxacin,citalopram,diltiazem,entacapone,fenofibrate,fish oil,mango,miconazole vaginal suppositories,quilinggao,sertraline,voriconazole,and zileuton), 5 reporting inhibition (etodolac,mercaptopurine,mesalamine,ribavirin,and trazodone), and 22 reporting “no effect” (anastrozole,argatroban,cilostazol,clopidogrel,donepezil hydrochloride,eprosartan,entacapone,gemifloxacin,levetiracetam,losartan,meloxicam,metrifonate,miglitol,modafinil,moexipril,montelukast,nateglinide,nefazodone,olestra,pantoprazole,sevelamer hydrochloride,and vitamin E).For 38 drugs or foods, level II causation (probable) criteria were met, and for the remaining 41 drugs or foods, the evidence was even less conclusive. Only 57 (31%) of the studies ruled out potential confounders, and fewer than 20% of the articles provided rechallenge data, demonstration of a dose response relationship, or a description of a previous exposure in which the patient experienced a similar effect.Of all 184 reviewed reports, 128 (70%) described a potentiation of warfarin’s effect, while inhibition and “no effect” reports each comprised 28 (15%). There were 34 reports of a major interaction—3 case reports of thrombosis associated with trazodone, sulfasalazine, and propofol and 31 case reports describing a major potentiation. These included 8 deaths, 4 of which were due to intracranial bleeding associated with celecoxib, ciprofloxacin, and fluoxetine/diazepam coadministration.Only 2 of all 34 reports were level I, describing inhibition involving mesalamine and trazodone.Several herbal drugs, foods rich in vitamin K, and carbamazepine were reported to decrease warfarin’s effect as were other anti-infective agents, including griseofulvin, rifampin, and penicillinase-resistant penicillins, such as nafcillin, dicloxacillin, and cloxacillin.There were 3 drugs—terbinafine, ritonavir, and influenza vaccine—for which conflicting evidence of an interaction with warfarin was presented.A cumulative summary, combining evaluations from our original reviewwith those of the update is presented in Table 2. Although few interactions met level I causation requirements, the recurrent reports on nonsteroidal anti-inflammatory drugs (NSAIDs),antibiotics (particularly macrolides—azithromycin,erythromycin,and clarithromycin), azoles (fluconazoleand miconazole), amoxicillin, and quinolones (ciprofloxacinand levofloxacin) continue. New alerts regarding the potential for major bleeding when warfarin is taken with cyclooxygenase-2 (COX-2) selective NSAIDsor herbal drugs are raised.Table 3presents a summary of all clinically significant potentiation and inhibition interactions with warfarin, based on drug family and level of causation.Table 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction*Level of CausationPotentiationInhibitionNo EffectI (Highly probable)AcetaminophenAlcohol (if concomitant liver disease)†Amiodarone†Anabolic steroids†Boldo-fenugreekCimetidine†Ciprofloxacin‡ (n = 34)Citalopram‡ (n = 12)Clofibrate†Cotrimoxazole†Diltiazem‡ (n = 20)Entacapone‡ (n = 12)Erythromycin†FenofibrateFish oilFluconazole†Isoniazid†MangoMetronidazole†Miconazole oral gel†Miconazole vaginal suppositoriesOmeprazole†Phenylbutazone†Piroxicam†Propafenone†Propranolol†QuilinggaoSertraline‡(n = 12)Sulfinpyrazone (biphasic with later inhibition)†Voriconazole‡ (n = 17)Zileuton‡ (n = 24)BarbituatesCarbamazepine†Chlordiazepoxide†Cholestyramine†Etodolac‡ (N = 18)Griseofulvin†MercaptopurineMesalamineNafcillin†RibavirinRifampin†Sucralfate†TrazodoneHigh vitamin K content foods/enteral feeds†Large amounts of avocado†Alcohol†Anastrozole‡ (N = 16)Antacids†Argatroban‡Atenolol†Bumetadine†Cilostazol‡ (N = 15)Clopidogrel‡ (N = 43)Diflunisal†Donepezil hydrochloride‡ (N = 12)Enoxacin†Eprosartan‡ (N = 18)Famotidine†Felodipine†Fluoxetine†Fondaparinux‡ (N = 12)Gemifloxacin‡ (n = 35)Ketorolac†Levetiracetam‡ (N = 26)Losartan‡ (N = 9)Meloxicam‡ (N = 13)Metoprolol†Metrifonate‡ (N = 14)Miglitol‡ (N = 19)Modafinil‡ (N = 28)Moexipril‡ (N = 10)Montelukast‡ (N = 12)Moricizine†Naproxen†Nateglinide‡ (N = 12)Nefazodone‡ (N = 17)Nizatidine†Olestra‡ (N = 36)Pantoprazole‡ (N = 26)Psyllium†Ranitidine†Sevelamer hydrochloride‡ (N = 14)Vitamin E‡ (N = 25)II (Probable)Acetylsalicylic acid†Amoxicillin/clavulanateAzithromycinCelecoxibChoral hydrate†ClarithromycinDanshenDextropropoxyphene†Disulfiram†Dong quaiFluorouracilFluvastatinFluvoxamineGemcitabineGrapefruit juiceInterferonItraconazole†Levamisole/fluorouracilLevofloxacinLycium barbarum LPC-SPESPaclitaxelParacetemolPhenytoin (biphasic with later inhibition)†Quinidine†RitonavirRopiniroleSimvastatin†Tamoxifen†Tetracycline†TolterodineTramadolTroglitazoneAzathioprineBosentanCandesartan cilexetil‡Chelation therapyDicloxacillin†GinsengInfluenza vaccineMultivitamin supplement containing vitamin KRaloxifene hydrochlorideRitonavirSoy milkAtorvastatinCilomilast‡ (N = 36)Coenzyme Q10/ginkgo biloba‡ (N = 24)Colesevelam hydrochlorideIbuprofen†Influenza vaccine†Ketoconazole†Ketoprofen†LevosimendanIII (Possible)AcarboseAmiodarone-induced toxicosisAmoxicillinAmoxicillin/tranexamic rinseCMF (cyclophosphamide/methotrexate/fluorouracil)ChloramphenicolCranberry juiceCurbicinDanazolDanshen/methyl salicylateDisopyramide†FelbamateGatifloxacinGemfibrozilIndomethacinIfosphamide†Lovastatin†LeflunomideMetolazone†Miconazole topical gelNalidixic acid†Norfloxacin†Ofloxacin†OrlistatPropoxyphene†RofecoxibTopical salicylates†SaquinavirSulindac†TerbinafineTiclopidineTolmetin†TrastuzumabCyclosporine†Etretinate†SulfasalazineSushi containing seaweedTelmisartanTerbinafineUbidicarenoneIV (Highly improbable)BezafibrateCefamandole†Cefazolin†Etoposide/carboplatinFluoxetine/diazepamHeparin†LevamisoleEvonorgestrelMethylprednisoloneNabumetoneQuetiapineSulfisoxazole†mFurosemideGreen teaNafcillin/dicloxacillinPropofolTeicoplaninTobacco†Vancomycin†*Interaction key: major interaction (bold/italics); moderate interaction (bold); minor interaction (italics); nonclinical interaction (regular).†Data from 1994 review.‡Drugs and foods for which evidence is based on fair- to good-quality randomized controlled trials; numbers in parentheses indicate number of subjects in trial.Table 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug GroupLevel of CausationAnti-infectivesCardiovascular DrugsAnalgesics, Anti-inflammatories and ImmunologicsCNS DrugsPotentiationI (Highly probable)CiprofloxacinCotrimoxazoleErythromycinFluconazoleIsoniazid (600 mg/d)MetronidazoleMiconazole oral gelMiconazole vaginal suppositoriesVoriconazoleAmiodaroneClofibrateDiltiazemFenofibratePropafenonePropranololSulfinpyrazone (biphasic with later inhibition)PhenylbutazonePiroxicamAlcohol (if concomitant liver disease)CitalopramEntacaponeSertralineII (Probable)Amoxicillin/clavulanateAzithromycinClarithromycinItraconazoleLevofloxacinRitonavirTetracyclineAcetylsalicylic acidFluvastatinQuinidineRopiniroleSimvastatinAcetaminophenAcetylsalicylic acidCelecoxibDextropropoxypheneInterferonTramadolDisulfiramChoral hydrateFluvoxaminePhenytoin (biphasic with later inhibition)III (Possible)AmoxicillinAmoxicillin/tranexamic rinseChloramphenicolGatifloxacinMiconazole topical gelNalidixic acidNorfloxacinOfloxacinSaquinavirTerbinafineAmiodarone-induced toxicosisDisopyramideGemfibrozilMetolazoneCelecoxibIndomethacinLeflunomidePropoxypheneRofecoxibSulindacTolmetinTopical salicylatesFelbamateIV (Highly improbable)CefamandoleCefazolinSulfisoxazoleBezafibrateHeparinLevamisoleMethylprednisoloneNabumetoneFluoxetine/diazepamQuetiapineInhibitionI (Highly probable)GriseofulvinNafcillinRibavirinRifampinCholestyramineMesalamineBarbituratesCarbamazepineII (Probable)DicloxacillinRitonavirBosentanAzathioprineChlordiazepoxideIII (Possible)TerbinafineTelmisartanSulfasalazineIV (Highly improbable)CloxacillinNafcillin/dicloxacillinTeicoplaninFurosemidePropofolPotentiationI (Highly probable)CimetidineFish oilMangoOmeprazoleBoldo-fenugreekQuilinggaoAnabolic steroidsZileutonII (Probable)Grapefruit juiceDanshenDong quaiLycium barbarum LPC-SPESFluorouracilGemcitabineLevamisole/fluorouracilPaclitaxelTamoxifenTolterodineIII (Possible)Cranberry juiceOrlistatDanshen/methyl salicylateAcarboseCMF (cyclophosphamide/methotrexate/fluorouracil)CurbicinDanazolIfosphamideTrastuzumabIV (Highly improbable)Etoposide/carboplatinLevonorgestrelInhibitionI (Highly probable)High vitamin K content foods/enteral feedsAvocado (large amounts)MercaptopurineII (Probable)Soy milkSucralfateGinsengChelation therapyInfluenza vaccineMultivitamin supplementRaloxifene hydrochlorideIII (Possible)Sushi containing seaweedCyclosporineEtretinateUbidicarenoneIV (Highly improbable)Green tea Abbreviations: CNS, central nervous system; GI, gastrointestinal.The most commonly cited mechanisms for interactions with warfarin involved stereoselective clearance due to S-enantiomer (ritonavir and cotrimoxazole) or nonstereoselective clearance (simvastatin and terbinafine) or the vitamin K pathway (green tea). However, most of the interactions reported have no documented mechanism.COMMENTThis updated review indicates that the number of reports of interactions between warfarin and drugs or foods is increasing, reaffirming both the anticoagulant’s widespread use and its use with concomitant medications. Although the true mechanisms of drug interactions almost always remain unknown, there are several pharmacokinetic and pharmacodynamic factors that could influence warfarin’s effect. Cholestyramine is thought to reduce the gastrointestinal absorption of warfarin.The more potent warfarin S-isomer is metabolized by cytochrome P-450 (CYP) 2C9. Many of the drugs identified as potentiating warfarin’s effect are known inhibitors of CYP 2C9, including amiodarone, fluconazole, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, and sertraline.Rifampin and secobarbital are both known inducers of CYP 2C9.The R-isomer of warfarin is metabolized by CYP 1A2 and CYP 3A4, and quinolonesinhibit CYP 1A2, and macrolidesinhibit CYP 3A4. The azoles (several reports involving metronidazole, fluconazole, trimethoprim-sulfamethoxazole, miconazole, and voriconazole) are also considered to inhibit CYP 1A2 or CYP 3A4. The pharmacodynamics of warfarin may be influenced by medications that affect either vitamin K or the coagulation factors.Sudden changes in dietary sources of vitamin K such as leafy greens or a supplemented diet followed by a change in warfarin’s effect are relatively easy to understand.However, for several drugs, including cephalosporins, levothyroxine, and clofibrate, their supposed pharmacodynamic interactions with warfarin are very poorly understood.Although understanding a drug’s pharmacology helps predict its potential for interaction with warfarin, the translation of these predictions into clinical reality is far from certain. We also found no evidence that specific factors might identify patient subgroups most at risk of pharmacokinetic drug interactions. Regular monitoring of INR remains the best protection against major harm due to these pharmacokinetic and pharmacodynamic interactions.The most difficult groups of drugs to deal with are those that potentiate bleeding on their own. The risk of bleeding is then greater when taken with warfarin, and INR monitoring is of no help. This is an issue with other anticoagulants (such as heparin), antiplatelet drugs (eg, acetylsalicylic acid, clopidogrel, dipyridamole, sulfinpyrazone, and ticlopidine) and all NSAIDs including COX-2 selective NSAIDs. All of these drugs should be avoided in combination with warfarin unless proven to provide benefit that outweighs the risk of bleeding—for example, for artificial heart valves.Contrary to the early theories of safety of COX-2 selective NSAIDs, we do not consider them safe in combination with warfarin. Both celecoxib (10 cases moderateto major) and rofecoxib (2 cases moderate) are reported to potentiate anticoagulation. Acetaminophen, which is the analgesic of choice for patients using warfarin, has case reportsas well as a case-control studysuggesting moderate potentiation (perhaps based on mild factor VII depletion), although findings from an RCT in healthy volunteers were negative.The paradox noted in our original review continues, in that higher-quality studies describe minor or no interaction, while clinically important potentiation or inhibition interactions all originate from poor-quality reports. The overall quality of the interaction literature remains extremely poor, precluding definitive recommendations regarding the safe coadministration or avoidance of specific drugs and foods in users of warfarin. Case reports may be alarming, but their rarity and the lack of a control group, a denominator of use, or often even basic descriptive details makes it impossible to gauge their true accuracy or rate of harm. Small RCTs of new drugs given with warfarin are increasingly common as a result of demands of regulators. These studies, which are invariably carried out with healthy young male volunteers, are too small to provide any assurance of lack of interaction and are likely not generalizable to the usual warfarin consumer—an elderly person with active medical conditions using several other medications. Only 5 of 34 RCTs evaluated in this review involved sample sizes from 24 to 43 patients.Poor-quality literature is not merely an aggravation to review. Twenty of the interaction reports received a level IV causation rating, implying that the interaction was highly improbable based on the lack of fulfillment of basic causation criteria.The publication of such reports is potentially harmful itself because it may generate unwarranted concern and erroneously influence prescribing. We were surprised to find no analyses of linked, large administrative databases examining drug interactions with warfarin.This review has several limitations. Our literature search did not solicit all unpublished adverse interactions reported to drug manufacturers or governments. However, both Health Canada’s Canadian Adverse Drug Reaction Monitoring Program and Food and Drug Administration’s MedWatch were solicited for cases. We also were unable to review all non-English publications. The handling of conflicting evidence, while sensible, could have led to a mistaken conclusion. Others may not agree with our multidimensional, hierarchical evaluation methods.In the extreme, no drug can be deemed “safe” based on our summary chart because the absence of proof of a severe interaction does not mean proof of absence. Idiosyncratic reactions can always be expected. We therefore continue to recommend careful monitoring of warfarin therapy at the time of introduction of any new medication, herbal product, or food. Herbal products are particularly problematic given the lack of quality control on their contents and the failure of clinicians to ask about their use.How can clinicians use this information? To prescribe safely, there are 3 choices: one is to never prescribe or allow another medicine to be given with warfarin. This is clearly impractical for most patients requiring warfarin. The second is to use an electronic medical record or prescribing system that will evaluate interactions among the patient’s entire profile of therapies.Because these systems are not available to most physicians and are frequently incomplete and sometimes inaccurate, a third approach is required. The third option is to group the majority of offending interacting drugs into easier-to-remember families or therapeutic groups, as we have done in Table 3. We recommend to exercise caution when adding any antibiotic to warfarin therapy, especially for macrolides, quinolones, and “azoles.” Many common cardiovascular drugs, including statins, fibrates, heparin, aspirin, and amiodarone, are problematic. Also, NSAIDs, including COX-2 selective NSAIDs, should be avoided, as should omeprazole, alcohol, chloral hydrate, anabolic steroids, and a wide variety of, if not all, herbal supplements. New oral anticoagulants may soon be available but have not demonstrated superior long-term efficacy, safety, or drug interaction profile compared with warfarin.CONCLUSIONSIn summary, there is an abundance of medications and foods for which an adverse interaction with warfarin, generally potentiation of warfarin’s effect, has been reported. While the drug interaction literature is generally of poor quality, relatively consistent reporting of interactions between warfarin and certain commonly used drugs and drug families (mainly anti-infective agents, lipid-lowering drugs, NSAIDs including COX-2 selective NSAIDs, selective serotonin reuptake inhibitors, amiodarone, omeprazole, fluorouracil, and cimetidine) is cause for concern. In patients who are starting therapy with one of these medicines, consideration should be given to using an alternative medication with less potential for warfarin interactions (eg, rabeprazole instead of omeprazole and acetaminophen instead of NSAIDs). More frequent INR testing during the 2 weeks of the onset or discontinuation of treatment with other medications is advisable. Finally, we recommend the use of more rigorous methods to examine warfarin interactions in patients (eg, RCTs, N of 1 crossover studies, or large health database analyses).Correspondence:Anne M. Holbrook, MD, PharmD, MSc, FRCPC, Division of Clinical Pharmacology, McMaster University, c/o Centre for Evaluation of Medicines, 105 Main St E, Level P1, Hamilton, Ontario, Canada L8N 1G6 (holbrook@mcmaster.ca).Accepted for Publication:December 21, 2004.REFERENCESGWAlbersJEDalenALaupacisWJManningPPetersenDESingerAntithrombotic therapy in atrial fibrillation.Chest2001119(suppl)194S206S11157649PDSteinJSAlpertHIBusseyJEDalenAGGTurpieAntithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest2001119(suppl)220S227S[published correction appears in Chest. 2001;120:1044]11157651TMAGHyersRDHullTAMorrisMSamamaVTapsonJGWegAntithrombotic therapy for venous thromboembolic disease.Chest2001119(suppl)176S193S11157648JACairnsPTherouxHDLewisJrMEzekowitzTWMeadeAntithrombotic agents in coronary artery disease.Chest2001119(suppl)228S252S[published correction appears in Chest. 2001;120:1427]11157652JHirshJDalenDRAndersonOral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range.Chest2001119(suppl 1)8S21S11157640PSWellsAMHolbrookNRCrowtherJHirshInteractions of warfarin with drugs and food.Ann Intern Med19941216766837944078RJBeythLMQuinnCSLandefeldProspective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.Am J Med199810591999727814JLFleissStatistical Methods for Rates and Proportions.New York, NY: John Wiley & Sons; 1981:212-225JAStadingMZSkrabalMAFaulknerSeven cases of interaction between warfarin and cyclooxygenase-2 inhibitors.Am J Health Syst Pharm2001582076208011715832TLMersfelderLRStewartWarfarin and celecoxib interaction.Ann Pharmacother20003432532710917378GDWoodTDeebleWarfarin: dangers with antibiotics.Dent Update1993203503538056109NPBeckeyLBKormanDParraEffect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.Pharmacotherapy1999191075107910610014JMKimRHWhiteEffect of vitamin E on the anticoagulant response to warfarin.Am J Cardiol1996775455468629604CLidellLESvedbergPLindellSBandhBJobLWallentinClopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation.Thromb Haemost20038984284612719782JEngelsenJDNielsenKEHansenEffect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial.Ugeskr Laeger20031651868187112772396DSIsraelJStotkaWRockEffect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.Clin Infect Dis1996222512568838180MGGebauerKNyfort-HandsenPJHenschkeASGallusWarfarin and acetaminophen interaction.Pharmacotherapy20032310911212523469JLambertJCormierPotential interaction between warfarin and boldo-fenugreek.Pharmacotherapy20012150951211310527MPriskornJSSidhuFLarsenJDDavisAZKhanPERolanInvestigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.Br J Clin Pharmacol1997441992029278211AMStoysichBDLucasSMMohiuddinDEHillemanFurther elucidation of pharmacokinetic interaction between diltiazem and warfarin.Int J Clin Pharmacol Ther19963456608929747JDingemanseCMeyerhoffJSchadrackEffect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.Br J Clin Pharmacol20025348549111994054KJAscahGARockPSWellsInteraction between fenofibrate and warfarin.Ann Pharmacother1998327657689681093MSBuckleyADGoffWEKnappFish oil interaction with warfarin.Ann Pharmacother200438505314742793JMonterrey-RodriguezInteraction between warfarin and mango fruit [letter].Ann Pharmacother20023694094112014355DJThirionLAZanettiPotentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories.Pharmacotherapy200020989910641982ALNWongTYKChanInteraction between warfarin and the herbal product quilinggao.Ann Pharmacother20033783683812014354GApseloffKDWilnerNGerberLMTremaineEffect of sertraline on protein binding of warfarin.Clin Pharmacokinet199732(suppl 1)37429068934LPurkinsNWoodDKleinermansDNicholsVoriconazole potentiates warfarin-induced prothrombin time prolongation.Br J Clin Pharmacol200356242914616410WMAwniZHusseinGRGrannemanKJPattersonLMDubeJHCavanaughPharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.Clin Pharmacokinet199529(suppl 2)67768620673JCErmerDRHicksSCWheelerMKramlWJJuskoConcomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin.Clin Pharmacol Ther1994553053168143396LAMartinSDMehtaDiminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy.Pharmacotherapy20032326026412587816MAMarinellaMesalamine and warfarin therapy resulting in decreased warfarin effect.Ann Pharmacother1998328418429681104SSchulmanInhibition of warfarin activity by ribavirin.Ann Pharmacother200236727411816263NLSmallKAGiamonnaInteraction between warfarin and trazodone.Ann Pharmacother20003473473610860134RAYatesJWongMSeiberlingMMerzWMarzMNauckThe effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers.Br J Clin Pharmacol20015142943511422000PMBrownMJHurstingLack of pharmacokinetic interactions between argatroban and warfarin.Am J Health Syst Pharm2002592078208312434720SMallikaarjunSLBramerEffect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.Clin Pharmacokinet199937(suppl 2)798610702890PJTiseoKFoleyLTFriedhoffThe effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.Br J Clin Pharmacol199846(suppl 1)45509839766DJKazieradDEMartinBIlsonEprosartan does not affect the pharmacodynamics of warfarin.J Clin Pharmacol1998386496539702851RAFaaijJBurggraafRCSchoemakerRGMvan AmsterdamAFCohenAbsence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.Br J Clin Pharmacol20025430430812236851MDavyNBirdKLRostHFuderLack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.Chemotherapy19994549149510567780IRagueneau-MajlessiRHLevyCMeyerhoffLack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.Epilepsy Res200147556311673021ANKongLTomaskoSAWaldmanLosartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.J Clin Pharmacol199535100810158568008DTurckCASuGHeinzelUBuschEBluhmkiJHoffmannLack of interaction between meloxicam and warfarin in healthy volunteers.Eur J Clin Pharmacol1997514214259049585RHeinigNKitchinPRolanDisposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate.Clin Drug Invest199918151159RSchallFOMullerHKHundtLDuursemaGGroenewoudMVMiddleStudy of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.Arzneimittelforschung19964641468821516PRobertsonJrETHellriegelSAroraMNelsonEffect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers.J Clin Pharmacol20024220521411831544AVan HeckenRVerbesseltMDepreMoexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.Eur J Clin Pharmacol1993452912938276058AVan HeckenMDepreRVerbesseltEffect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.J Clin Pharmacol19993949550010234597DMAndersonSShelleyNCrickMBuraglioNo effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.J Clin Pharmacol2002421358136512463731DESalazarRCDockensRLMilbrathPharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects.J Clin Pharmacol1995357307387560254LDuursemaFOMullerRSchallLack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.Br J Clin Pharmacol1995397007037654493SBurkeNAminCIncertiMPloneNWatsonSevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics.J Clin Pharmacol20014119319811210401DCByrdSEGaskinsAMParrishLBFreemanWarfarin and ciprofloxacin interaction: case report and controversy.J Am Board Fam Pract19991248648810612367MMcMorranIMorawieckaCelecoxib (Celebrex): 1 year later.CMAJ200016210441046, 1048-105010763409LADentMWOrrockWarfarin-fluoxetine and diazepam-fluoxetine interaction.Pharmacotherapy1997171701729017779MGuerretPFrancheteauMHuberEvaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers.Pharmacotherapy1997177677739250555JAWarwickRJCorrallSerious interaction between warfarin and oral terbinafine.BMJ19983164409492670AKGuptaGSRossInteraction between terbinafine and warfarin.Dermatology19981962662679568423GNewshanPTsangRitonavir and warfarin interaction.AIDS1999131788178910509586DPoliLChiarugiMCapanniNeed of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination.Blood Coagul Fibrinolysis20021329730012032394BALipskyREPecoraroNJRobenPde BlaquiereCJDelaneyInfluenza vaccination and warfarin anticoagulation.Ann Intern Med19841008358376721299PKramerMTsuruCECookCJMcClainJLHoltzmanEffect of influenza vaccine on warfarin anticoagulation.Clin Pharmacol Ther1984354164186697649LDuursemaFOMullerHKHundtADHeynsBHMeyerHGLuusModel to detect warfarin-drug interactions in man.Drug Investig19924395402LDHeimarkLWienkersKKunzeThe mechanism of the interaction between amiodarone and warfarin in humans.Clin Pharmacol Ther1992513984071563209SAlmogNShafranHHalkinMechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination.Eur J Clin Pharmacol1985282572614007030RAO'ReillyWFTragerAERettieDAGoulartInteraction of amiodarone with racemic warfarin and its separated enantiomorphs in humans.Clin Pharmacol Ther1987422902943621782KPyoralaGMyllylaMKekkiMetabolism of warfarin during methandrostenolone treatment.Ann Med Exp Biol Fenn19654395975317992SMLorentzRTWeibertPotentiation of warfarin anticoagulation by topical testosterone ointment.Clin Pharm198543323344006400SToonKJHopkinsFMGarstangMRowlandComparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.Eur J Clin Pharmacol1987321651723582481RAO'ReillyComparative interaction of cimetidine and ranitidine with racemic warfarin in man.Arch Intern Med19841449899916324710WRBellKCAndersonDANoeBASilverReduction in the plasma clearance rate of warfarin induced by cimetidine.Arch Intern Med1986146232523283778066MJSerlinRGSibeonSMossmanCimetidine: interaction with oral anticoagulants in man.Lancet1979231731989387MJSaxWCRandolphKEPeaceEffect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy.Clin Pharm19876492495[published correction appears in Clin Pharm. 1988;7:269]3690995BAHuntMJSaxSChretienWOFrankAJBravermanStereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens.Pharmacotherapy19899184RAO'ReillyMASahudAJRobinsonStudies on the interaction of warfarin and clofibrate in man.Thromb Diath Haemorrh1972273093184340370RAO'ReillyCHMotleyRacemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.Ann Intern Med1979913436464451RTWeibertSMLorentzRJTownsendCECookMRKlauberPIJaggerEffect of erythromycin in patients receiving long-term warfarin therapy.Clin Pharm198982102142706893DBlackJEvansTSeatonBGidalNMcDonnellKKunzeEvaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract].Clin Pharmacol Ther199251piii-52ARRosenthalTHSelfEDBakerRALindenInteraction of isoniazid and warfarin.JAMA19772382177578833RAO'ReillyThe stereoselective interaction of warfarin and metronidazole in man.N Engl J Med1976295354357934223RAO'ReillyDAGoulartKLKunzeMechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.Clin Pharmacol Ther1992516566671611805TSutfinKBalmerHBostromSErikssonPHoglundOPaulsenStereoselective interaction of omeprazole with warfarin in healthy men.Ther Drug Monit1989111761842718223PMAggelerRAO'ReillyLLeongPEKowitzPotentiation of anticoagulant effect of warfarin by phenylbutazone.N Engl J Med19672764965016018280RAO'ReillyWFTragerCHMotleyWHowaldStereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man.J Clin Invest1980657467537354137RSRhodesPJRhodesCKleinCDSintekA warfarin-piroxicam drug interaction.Drug Intell Clin Pharm1985195565584028961REKatesYGYeeEBKirstenInteraction between warfarin and propafenone in healthy volunteer subjects.Clin Pharmacol Ther1987423053113621785AKScottBKParkAMBreckenridgeInteraction between warfarin and propranolol.Br J Clin Pharmacol198417(suppl 1)86S6743477NDBaxMSLennardGTTuckerThe effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin.Br J Clin Pharmacol198417(suppl 1)85S6146343GGNenciGAgnelliMBerrettiniBiphasic sulphinpyrazone-warfarin interaction.Br Med J (Clin Res Ed)1981282136113626786498RAO'ReillyStereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.Circulation1982652022077053283SToonLKLowMGibaldiThe warfarin-sulfinpyrazone interaction: stereochemical considerations.Clin Pharmacol Ther19863915243943265RAO'ReillyWFTragerCHMotleyWHowaldInteraction of secobarbital with warfarin pseudoracemates.Clin Pharmacol Ther1980281871957398186MOrmeABreckenridgeEnantiomers of warfarin and phenobarbital.N Engl J Med197629514821483995149JMHansenKSiersboek-NielsenLSkovstedCarbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man.Clin Pharmacol Ther1971125395435567804ABreckenridgeMOrmeClinical implications of enzyme induction.Ann N Y Acad Sci19711794214305285387DSRobinsonDMBenjaminJJMcCormackInteraction of warfarin and nonsystemic gastrointestinal drugs.Clin Pharmacol Ther1971124914955567801EJahnchenTMeinertzHJGilfrichFKerstingUGrothEnhanced elimination of warfarin during treatment with cholestyramine.Br J Clin Pharmacol19785437440656283KOkinoRTWeibertWarfarin-griseofulvin interaction.Drug Intell Clin Pharm1986202912933698827SICullenPCatalanoGriseofulvin-warfarin antagonism.JAMA19671995825836071326GDQureshiTPReindersGJSomoriHJEvansWarfarin resistance with nafcillin therapy.Ann Intern Med19841005275296703546RAO'ReillyInteraction of sodium warfarin and rifampin: studies in man.Ann Intern Med1974813373404852505LDHeimarkMGibaldiWFTragerRAO'ReillyDAGoulartThe mechanism of the warfarin-rifampin drug interaction in humans.Clin Pharmacol Ther1987423883943665337DMungallRLTalbertCPhillipsDJaffeTMLuddenSucralfate and warfarin [letter].Ann Intern Med1983985576687662RLTalbertCDalmady-IsraelHIBusseyMHCrawfordTMLuddenEffect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy.Drug Intell Clin Pharm19851959GDQureshiTPReindersJJSwintMBSlateAcquired warfarin resistance and weight-reducing diet.Arch Intern Med19811415075097212893MDParrKERecordGLGriffithJVZeokEPToddEffect of enteral nutrition on warfarin therapy.Clin Pharm198212742766821036DBlicksteinMShaklaiAInbalWarfarin antagonism by avocado [letter].Lancet19913379149151672990RAO'ReillyLack of effect of fortified wine ingested during fasting and anticoagulant therapy.Arch Intern Med19811414584597212888RAO'ReillyLack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants.Am J Med Sci1979277189194463946HNipperSKirbyFLIberEffect of bumetanide on the serum disappearance of warfarin sodium.J Clin Pharmacol1981216546567338576MJSerlinSMossmanRGSibeonKFTemperoAMBreckenridgeInteraction between diflunisal and warfarin.Clin Pharmacol Ther1980284934987408409SToonKJHopkinsFMGarstangLAaronsASedmanMRowlandEnoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.Clin Pharmacol Ther19874233413474093IDe LepeleireAVan HeckenRVerbesseltLack of interaction between famotidine and warfarin.Int J Clin Pharmacol Res1990101671712228341MGrindMMurphySWarringtonJAbergMethod for studying drug-warfarin interactions.Clin Pharmacol Ther1993543813878222480HRoweRCarmichaelLLembergerThe effect of fluoxetine on warfarin metabolism in the rat and man.Life Sci197823807812309056SToonBLHoltFGMullinsRBullinghamLAaronsMRowlandInvestigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin.Br J Clin Pharmacol1990307437502271374IHBenedekSYKingRJPowellAMAgraWLScharyHJPieniaszekJrEffect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.J Clin Pharmacol1992325585631634644AJainFGMcMahonJTSlatteryGLevyEffect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin.Clin Pharmacol Ther1979256166758244ACournotIBerlinJCSallordESinglasLack of interaction between nizatidine and warfarin during chronic administration.J Clin Pharmacol198828112011222907521MJSerlinRGSibeonAMBreckenridgeLack of effect of ranitidine on warfarin action.Br J Clin Pharmacol1981127917946122462MOrmeABreckenridgePCookWarfarin and distalgesic interaction.BMJ197612001247776LDavydovMYermolnikLJCuniWarfarin and amoxicillin/clavulanate drug interaction.Ann Pharmacother20033736737012639164DRFosterNLMilanPotential interaction between azithromycin and warfarin.Pharmacotherapy19991990290810417043JAUdallWarfarin interactions with chloral hydrate and glutethimide.Curr Ther Res Clin Exp1975176774806430MByersClarithromycin-warfarin interaction resulting in an elevated INR.Can J Hosp Pharm199750285287MBIzzatAPYimMHEl ZufariA taste of Chinese medicine.Ann Thorac Surg1998669419429768962RSmithDPruddenCHawkesPropoxyphene and warfarin interaction [letter].Drug Intell Clin Pharm1984188226489165RAO'ReillyDynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin.Clin Pharmacol Ther1981293323367471603RLPageJDLawrencePotentiation of warfarin by dong quai.Pharmacotherapy19991987087610417036JCarabinoFWangInternational normalized ratio fluctuation with warfarin-fluorouracil therapy [letter].Am J Health Syst Pharm20025987512004471LETrilliCLKelleySLAspinallBAKronerPotential interaction between warfarin and fluvastatin.Ann Pharmacother199630139914028968451KKLimkeARSheltonESElliottFluvoxamine interaction with warfarin.Ann Pharmacother2002361890189212452751SAKinikarJMKolesarIdentification of a gemcitabine-warfarin interaction.Pharmacotherapy1999191331133310555940WRBartleGrapefruit juice might still be factor in warfarin response [letter].Am J Health Syst Pharm19995667610423213YAdachiYYokoyamaTNannoTYamamotoPotentiation of warfarin by interferon.BMJ19953112927543311JYehSCSooCSummertonCRichardsonPotentiation of action of warfarin by itraconazole.BMJ19903016692171705MAScarfeMKIsraelPossible drug interaction between warfarin and combination of levamisole and fluorouracil.Ann Pharmacother1994284644678038468SLRavnanCLockeLevofloxacin and warfarin interaction.Pharmacotherapy20012188488511444586AYLamGWElmerMAMohutskyPossible interaction between warfarin and Lycium barbarum L.Ann Pharmacother2001351199120111675844NBDavisLNahlikNJVogelzangDoes PC-SPES interact with warfarin?J Urol2002167179311912419METhompsonMSHighleyInteraction between paclitaxel and warfarin [letter].Ann Oncol20031450012598362DAFitzmauriceJAMurrayPotentiation of the anticoagulant effect of warfarin.Postgrad Med J1997734394409338037MLevineISheppardBiphasic interaction of phenytoin with warfarin.Clin Pharm198432002036723231JKoch-WeserQuinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy.Ann Intern Med1968685115175643674JDBairTFOppeltWarfarin and ropinirole interaction.Ann Pharmacother2001351202120411675845AGawDWosornuSimvastatin during warfarin therapy in hyperlipoproteinaemia [letter].Lancet19923409799801357387JCLinMKItoSNStolleyAPMorrealeDBMarcusThe effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin.J Clin Pharmacol19993986909987704RLodwickBMcConkeyAMBrownLife threatening interaction between tamoxifen and warfarin.Br Med J (Clin Res Ed)198729511413120919LKWestfallAn unrecognized cause of warfarin resistance [letter].Drug Intell Clin Pharm1981151317274023EADanosApparent potentiation of warfarin activity by tetracycline.Clin Pharm1992118068081521405VJColucciMPRiveyTolterodine-warfarin drug interaction.Ann Pharmacother1999331173117610573314JRSabbePJSimsMHSimsTramadol-warfarin interaction.Pharmacotherapy1998188718739692666MLScherNHHuntingtonJAVitilloPotential interaction between tramadol and warfarin [letter].Ann Pharmacother1997316466479161668BKPlowmanAPMorrealePossible troglitazone-warfarin interaction [letter].Am J Health Syst Pharm19985510719606460MRotenbergYLevyYShoenfeldSAlmogDEzraEffect of azathioprine on the anticoagulant activity of warfarin.Ann Pharmacother20003412012210669196LMMurpheyEHHoodBosentan and warfarin interaction.Ann Pharmacother2003371028103112841813JHJonkmanJJvan LierPNvan HeiningenRLinsRSennewaldAHogemannPharmacokinetic drug interaction studies with candesartan cilexetil.J Hum Hypertens199711(suppl 2)S31S359331003HBGrebePJGregoryInhibition of warfarin anticoagulation associated with chelation therapy.Pharmacotherapy2002221067106912173793PMKrstenanskyWNJonesHSGarewalEffect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium.Clin Pharm198768048063505843ATMaillouxBEGidalCASorknessPotential interaction between warfarin and dicloxacillin.Ann Pharmacother199630140214078968452MFRosadoThrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product.Cardiology20039911112711887DKurnikALubetskyRLoebsteinSAlmogHHalkinMultivitamin supplements may affect warfarin anticoagulation in susceptible patients.Ann Pharmacother2003371603160614565795JWMillerASkerjanecMPKnadlerAGhoshSRBAllerheiligenDivergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin.Pharm Res2001181024102811496940KRKnoellTMYoungESCousinsPotential interaction involving warfarin and ritonavir.Ann Pharmacother199832129913029876810JACambria-KielyEffect of soy milk on warfarin efficacy.Ann Pharmacother2002361893189612452752RSternRAbelGLGibsonJBessererAtorvastatin does not alter the anticoagulant activity of warfarin.J Clin Pharmacol199737106210649506000JKellyRDMurdochDJClarkDMWebberHFuderWarfarin pharmacodynamics unaffected by cilomilast.Ann Pharmacother2001351535153911793614JMDonovanDStypinskiMRStilesTAOlsonSKBurkeDrug interactions with colesevelam hydrochloride: a novel potent lipid-lowering agent.Cardiovasc Drugs Ther20001468169011300370SSchulmanKHenrikssonInteraction of ibuprofen and warfarin on primary haemostasis.Br J Rheumatol19892846492783873CBrassJNGalgianiTFBlaschkeRDefeliceRAO'ReillyDAStevensDisposition of ketoconazole an oral antifungal in humans.Antimicrob Agents Chemother1982211511586282204CMieszczakKWintherLack of interaction of ketoprofen with warfarin.Eur J Clin Pharmacol1993442052068453969SAntilaAJarvinenTHonkanenLLehtonenPharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin.Eur J Clin Pharmacol20005670571011214780APMorrealeKJanetzkyProbable interaction of warfarin and acarbose.Am J Health Syst Pharm199754155115529217947KAWoeberIWarnerPotentiation of warfarin sodium by amiodarone-induced thyrotoxicosis.West J Med199917049519926737TBandrowskyAAVoronoTJBorrisHWMarcantoniAmoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses.Oral Surg Oral Med Oral Pathol Oral Radiol Endod1996826106128974131PMalacarneAMaestriPossible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter].Recenti Prog Med1996871358650435RLeoneEGhiottoAConfortiGVeloPotential interaction between warfarin and ocular chloramphenicol [letter].Ann Pharmacother1999331149972397RSuvarnaMPirmohamedLHendersonPossible interaction between warfarin and cranberry juice.BMJ2003327145414684645QYueKJanssonHerbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component [letter].J Am Geriatr Soc20014983811454132CDBoothDrug interaction between danazol and warfarin.Pharm J1993250439440LSTamTYChanWKLeungJACritchleyWarfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter].Aust N Z J Med1995252587487701CSylvenPAndersonEvidence that disopyramide does not interact with warfarin.Br Med J (Clin Res Ed)198328611816404381EHaworthAKBurroughsDisopyramide and warfarin interaction.BMJ19772866867922330KATisdelDSIsraelKWKolbWarfarin-felbamate interaction: first report [letter].Ann Pharmacother1994288057919574RJArtymowiczBJCinoJGRossiJLWalkerSMoorePossible interaction between gatifloxacin and warfarin.Am J Health Syst Pharm2002591205120612073864JPRindoneHCKengGemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.Chest19981146416429726762TYChanSFLuiSYChungSLukJACritchleyAdverse interaction between warfarin and indomethacin.Drug Saf1994102672697880236GHallMJLindMHuangIntravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control.Postgrad Med J1990668608612129174SAhmadLovastatin: warfarin interaction.Arch Intern Med199015024072241455VLimIPandeLeflunomide can potentiate the anticoagulant effect of warfarin.BMJ2002325133312468482VFTrewinA probable interaction between warfarin and metolazone.Pharm J198818781782JEvansDSOrmeMLSedgwickGRYoungsTreating oral candidiasis: potentially fatal [letter].Br Dent J19971824529231515JLeorDLevartowskyCSharonInteraction between nalidixic acid and warfarin [letter].Ann Intern Med19871076013631807TLinvilleDMataninNorfloxacin and warfarin.Ann Intern Med19891107517522930115JLeorSMatetzkiOfloxacin and warfarin [letter].Ann Intern Med19881097613190063AMBaciewiczBHAsharTWLockeInteraction of ofloxacin and warfarin [letter].Ann Intern Med199311912238239258RSMacWalterHWFraserKMArmstrongOrlistat enhances warfarin effect.Ann Pharmacother20033751051212659605FLittletonWarfarin and topical salicylates [letter].JAMA199026328882338749WHChowKLCheungHMLingTSeePotentiation of warfarin anticoagulation by topical methylsalicylate ointment.J R Soc Med1989825015022778785MRDarlingtonHypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter].Ann Pharmacother1997316479161669SACarterPotential effect of sulindac on response of prothrombin-time to oral anticoagulants.Lancet1979269869990792JRRossLBeeleySulindac prothrombin time and anticoagulants [letter].Lancet19792107591811BEGidalCASorknessKAMcGillRLarsonRRLevineEvaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients.Ther Drug Monit19951733387725374JFKorenDLCochranRLJanesTolmetin-warfarin interaction.Am J Med198782127812803605152MJNissenblattGIKarpBleeding risk with trastuzumab (Herceptin) treatment.JAMA19992822299230110612314DSSnyderInteraction between cyclosporine and warfarin [letter].Ann Intern Med19881083113124684LSOstlereJALangtrySJonesRCStaughtonReduced therapeutic effect of warfarin caused by etretinate [letter].Br J Dermatol19911245052039731AMTeefyJEMartinMJKovacsWarfarin resistance due to sulfasalazine.Ann Pharmacother2000341265126811098339WRBartlePMadorinFGuylaineSeaweed, vitamin K, and warfarin [letter].Am J Health Syst Pharm200158230011763808JStangierCASuMGHendriksSteady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers.J Clin Pharmacol2000401331133711185631OSpigsetReduced effect of warfarin caused by ubidecarenone [letter].Lancet1994344137213737968059TRBeringerWarfarin potentiation with bezafibrate.Postgrad Med J1997736576589497982DMAngaranVCDiasKVAromThe comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: cefamandole cefazolin vancomycin.Ann Surg19872061551613300580ATLeNKHassonBLLumEnhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy.Ann Pharmacother199731100610089296241PThomasAFennertyGBlackhouseOral anticoagulant during treatment with heparin.Br Med J (Clin Res Ed)19842881916419853TWWehbeJAWarthA case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole.Clin Pharmacol Ther1996593603628653999JEllisonApparent interaction between warfarin and levonorgestrel used for emergency contraception.BMJ2000321138211099283MKaufmanTreatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin.Mult Scler199732482499372508VCDennisBKThomasJEHanlonPotentiation of oral anticoagulation and hemarthrosis associated with nabumetone.Pharmacotherapy20002023423910678303TRogersJde LeonDAtcherPossible interaction between warfarin and quetiapine [letter].J Clin Psychopharmacol19991938238310440472LJSiorisRTWeibertPRPentelPotentiation of warfarin anticoagulation by sulfisoxazole.Arch Intern Med19801405465477362390OMIbrahimAAllamWarfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin.Saudi Pharm J199645659SCLaizureLMadlockMCyrTSelfDecreased hypoprothrombinemic effect of warfarin associated with furosemide.Ther Drug Monit1997193613639200780JRTaylorVMWiltProbable antagonism of warfarin by green tea.Ann Pharmacother19993342642810332534SMSetterKLawlessKAHunterNeed for continuity of care in patients receiving warfarin and nafcillin/dicloxacillin.Hosp Pharm19963112691271RMacLarenBAWachsmanDKSwiftDAKuhlWarfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature.Pharmacotherapy199717133113379399621FGAgostaNLLiberatoFChiofaloWarfarin resistance induced by teicoplanin [letter].Haematologica1997826376389407741JRMayJTDiPiroJFSisleyDrug interactions in surgical patients.Am J Surg19871533273352881497GMGabbFatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter].Med J Aust19961647007018657040AMBaciewiczJJMenkeJABokarEBBaudFluconazole-warfarin interaction [letter].Ann Pharmacother19942811117803894KKHaaseCHRojas-FernandezLLaneDAFrankPotential interaction between celecoxib and warfarin.Ann Pharmacother20003466666710852097KJanetzkyAPMorrealeProbable interaction between warfarin and ginseng.Am J Health Syst Pharm1997546926939075501AMHolbrookPSWellsNRCrowtherPharmacokinetics and drug interactions with warfarin.In: Poller L, Hirsh J, eds. Oral Anticoagulants. Dunton Green, England: Hodder and Stoughton; 1996Indiana University Department of Medicine Web siteCytochrome P450 drug interaction table.Available at: http://medicine.iupui.edu/flockhart/table.htm.Accessed July 15, 2004RAO'ReillyStereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.N Engl J Med198030233357350395JHirshJAnsellJAnsellJLHalperinAmerican Heart Association/American College of Cardiology foundation guide to warfarin therapy.Circulation20031071692171112668507JEHarrisInteraction of dietary factors with oral anticoagulants: review and applications.J Am Diet Assoc1995955805847722194RAO'ReillyDRytand“Resistance” to warfarin due to unrecognized vitamin K supplementation [letter].N Engl J Med19803031601617383081FMPedersenOHamburgKHessLOvesenThe effect of dietary vitamin K on warfarin-induced anticoagulants.J Intern Med19912295175202045759JCOwensJBNeelyWROwenEffect of sodium dextrothyroxine in patients receiving anticoagulation.N Engl J Med1962266767914482918AMAntlitzJAMeadJrMATolentinoPotentiation of oral anticoagulant therapy by acetaminophen.Curr Ther Res Clin Exp1968105015074971464EMHylekHHeimanSJSkatesMASheehanDESingerAcetaminophen and other risk factors for excessive warfarin anticoagulation.JAMA19982796576629496982DKwanWRBartleSEWalkerThe effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.J Clin Pharmacol19993968759987702LMGianniWBDreitleinSome popular OTC herbals can interact with anticoagulant therapy.US Pharm19982380, 8384, 86BSJoshiPNKaulAlternative medicine: herbal drugs and their critical appraisal—part I.Prog Drug Res20015617611417111AMHolbrookVJanjusevicKKeshavjeeHKLeeMeasuring quality of prescribing: where does the information reside? [abstract].Can J Clin Pharmacol2002940AMHolbrookKKeshavjeeCHGoldsmithJTuckerLParkAdvancing the measurement of quality of care using electronic medical records.Proc Towards Electron Patient Rec19991848855 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Internal Medicine American Medical Association

Systematic Overview of Warfarin and Its Drug and Food Interactions

Download PDF
12 pages

Loading next page...
 
/lp/american-medical-association/systematic-overview-of-warfarin-and-its-drug-and-food-interactions-LaK9oubt8M

References (243)

Publisher
American Medical Association
Copyright
Copyright 2005 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
2168-6106
eISSN
2168-6114
DOI
10.1001/archinte.165.10.1095
pmid
15911722
Publisher site
See Article on Publisher Site

Abstract

BackgroundWarfarin is a highly efficacious oral anticoagulant, but its use is limited by a well-founded fear of bleeding. Drug and food interactions are frequently cited as causes of adverse events with warfarin. We provide an updated systematic overview of the quality, clinical effect, and importance of these reported interactions.Data SourcesMEDLINE, TOXLINE, IPA, and EMBASE databases from October 1993 to March 2004. Database searches combined the keyword warfarinwith drug interactions, herbal medicines, Chinese herbal drugs, and food-drug interactions.Study SelectionEligible articles contained original reports of warfarin drug or food interactions in human subjects. Non-English articles were included if sufficient information could be abstracted.Data ExtractionReports were rated independently by 2 investigators for interaction direction, clinical severity, and quality of evidence. Quality of evidence was based on previously validated causation criteria and study design.Data SynthesisOf 642 citations retrieved, 181 eligible articles contained original reports on 120 drugs or foods. Inter-rater agreement was excellent, with weighted κ values of 0.84 to 1.00. Of all reports, 72% described a potentiation of warfarin’s effect and 84% were of poor quality, 86% of which were single case reports. The 31 incidents of clinically significant bleeding were all single case reports. Newly reported interactions included celecoxib, rofecoxib, and herbal substances, such as green tea and danshen.ConclusionsThe number of drugs reported to interact with warfarin continues to expand. While most reports are of poor quality and present potentially misleading conclusions, the consistency of reports of interactions with azole antibiotics, macrolides, quinolones, nonsteroidal anti-inflammatory drugs, including selective cyclooxygenase-2 inhibitors, selective serotonin reuptake inhibitors, omeprazole, lipid-lowering agents, amiodarone, and fluorouracil, suggests that coadministration with warfarin should be avoided or closely monitored. More systematic study of warfarin drug interactions in patients is urgently needed.Warfarin is the most commonly used oral anticoagulant in North America and has established efficacy for the prevention of thromboembolic events in patients with chronic atrial fibrillation, prosthetic heart valves, venous thromboembolism, and coronary artery disease.The drug is a racemic mixture of 2 optically active isomers, though the S-enantiomer is approximately 5 times more potent than the R-enantiomer. Warfarin exerts its effect by lowering the amount of active vitamin K available for the activation of clotting factors II, VII, IX, and X.Both effectiveness and safety (primarily risk of bleeding) are related to blood international normalized ratio (INR) values. Monitoring of INR and dose adjustments of warfarin are frequently required, influenced by changes in concomitant medications, diet, alcohol consumption, acute illness, liver disease, and unknown factors.Despite the frequency and importance of warfarin’s drug and food interactions, the first systematic overview on the topic did not appear until 1994.For that review, we developed an interaction assessment tool that combined a “levels of evidence” approach with causation criteria, subject outcome, and proposed mechanisms. Although many drugs, including antibiotics, drugs affecting the central nervous system, and cardiac medications, had been reported to interact with warfarin, the quality of reports was so poor that few clinical recommendations could be made other than careful monitoring around initiating and discontinuing treatment with other medications. In the decade since that review, awareness and investigation of drug interactions and quality of evidence have grown, leading to the hypothesis that the number and quality of drug and food interactions would increase as well. We therefore performed a systematic overview of the literature, updating the evidence on warfarin drug and food interactions.METHODSRelevant literature was identified by searching MEDLINE, TOXLINE, IPA, EMBASE databases, Health Canada and Food and Drug Administration Web sites and personal files from October 1993 to the end of March 2004. The MeSH headings and keywords used for the search were warfarinand drug interactions. Non-English articles were included if they included an English abstract with sufficient information. To retrieve warfarin-herbal drug interactions and warfarin-food interactions, 2 additional searches were conducted using the MeSH headings and keywords warfarinand herbal medicinesor Chinese herbal drugs, and MeSH headings food-drug interactionsand warfarin, limited to English only. The bibliographies of the retrieved articles were checked for any additional pertinent studies. Articles were considered eligible for evaluation if they contained original data involving drug or food interactions with warfarin in human subjects. Interacting drugs had to be available in the United States or Canada. Eligible studies were evaluated independently by 2 authors according to the following 4 main categories.SUBJECTSubjects were classified as patients or healthy volunteers. Patients were then further stratified into 2 categories: volunteers and nonvolunteers. The former group were defined as patients requiring warfarin therapy who were prospectively entered into a study, whereas the latter group was exposed to the interacting drug during the course of usual warfarin therapy. Healthy volunteers were healthy individuals not requiring warfarin therapy.INTERACTION CLASSIFICATION AND SEVERITYThe drug affected and the type of interaction (potentiation, inhibition, or no effect) were noted. Interactions that potentiated or inhibited the effect of warfarin were further rated as major, moderate, minor, or nonclinical.Major potentiation was defined by death, major bleeding, or necessity to stop warfarin therapy entirely. Major bleeding episodes included those that were life-threatening as well as those that led to the loss of at least 2 units of blood in 7 days or less.Moderate potentiation meant that (1) there was an INR change requiring an adjustment in warfarin dosage or (2) the INR increased to greater than 5.0 or (3) there was an increase in INR by greater than 1.5. Minor potentiation interactions were defined as an INR increase in which (1) no change in warfarin dosage was required and (2) the ratio remained less than 5 and (3) the increase was less than 1.5. Potentiation interactions were classified as nonclinical if the only evidence of warfarin augmentation was a statistically significant increase in warfarin levels without change in INR or clinical status.Major inhibition interactions were defined by the occurrence of thrombosis. Moderate inhibition (clinically relevant but less than major) indicated (1) a change in INR requiring an adjustment in warfarin dosage or (2) an INR decrease to less than 1.5 or (3) a decrease in INR by greater than 1.5 units. Minor inhibition interactions were defined by (1) an INR decrease requiring no change in warfarin dosage and (2) an INR decrease to a ratio that remained more than 1.5 and (3) a decrease in INR by less than 1.5. Inhibition interactions were classified as nonclinical if the only evidence of warfarin inhibition was a statistically significant decrease in warfarin levels.An interaction was defined as having no effect if the interacting drug neither potentiated nor inhibited warfarin’s effect in any way described herein.QUALITY OF STUDYReports were classified into 1 of 4 categories based on the quality of study design. As shown in Table 1, randomized controlled trials (RCTs) were subdivided into fair to excellent quality, with those involving more than 100 subjects arbitrarily given the highest rating. Poor quality reports included nonrandomized study designs, observational studies, pharmacokinetic studies, and case reports.Table 1. Quality of Study DesignQualityStudy DesignExcellentRCTs with >100 subjectsGoodRCTs with 20-100 subjectsFairRCTs with <20 subjectsPoor Group 1Observational studies (cohort, case-control) Group 2Case series, case reports, pharmacokinetic studiesAbbreviation: RCTs, randomized controlled trials.CAUSATION CRITERIAFor each report, the probability of the proposed interaction was rated from level I (highly probable) to level IV (highly improbable). Definitive evidence of an interaction required a level I causation rating from both healthy volunteer and patient-based reports in which both described identical interaction direction and severity. Level designation was based on how the article fulfilled 7 standard causation criteria.Level of CausationCausation Criteria RequiredI (Highly probable)A, B, C, and ≥1 of D to GII (Probable)A, B, and ≥1 of C to GIII (Possible)A and ≥1 of B to GIV (Highly improbable)A alone or any combination of B to GIs the timing correct for an interaction to be pharmacologically plausible? In patient-based studies, warfarin must have been taken at a stabilized dose common to usual practice and prior to initiation of the interacting drug or food. For volunteer-based studies, subjects had to have received warfarin, both alone as well as with the interacting drug. In addition, we required that the potentially interacting drug had to be consumed (1) long enough to attain a significant plasma level and (2) in doses common to usual practice.Do laboratory tests (eg, international normalized ratio/prothrombin time/thrombotest) support the contention of an interaction? In patient-based articles, the post-coadministration coagulation variable had to be out of therapeutic range, whereas for volunteer studies, a 20% change in coagulation parameters for volunteer studies was required. For articles concluding “no interaction,” the absence of a statistically significant change in coagulation variables was required.Are other potential factors affecting warfarin pharmacokinetics/pharmacodynamics ruled out satisfactorily? Factors such as diet, other medications, as well as certain medical conditions (hepatic dysfunction and hyperthyroidism) had to have been declared to be ruled out as possible causes of the outcome.Has the patient had a similar result with previous exposure to the same drug? The patient had to have been taking the interacting drug in addition to warfarin at a time prior to that reported with a similar outcome.Was a dose-response relationship demonstrated for the interacting drug? The alterations in the dose of the implicated interacting drug or food being administered with warfarin correlated with subsequent changes in coagulation variables, inferring a dose-response relationship.Was the subject rechallenged and, if so, did a similar response occur? The interacting drug had to have been administered simultaneously with warfarin in 2 or more separate courses (the second course conducted to confirm the results of the first), with similar results each time.Are the authors’ conclusions supported by other objective evidence? Other objective evidence such as plasma levels of warfarin or coagulation factors supported the authors’ conclusions.RELIABILITY AND VALIDITYThe criteria and rating scheme were evaluated and approved a priori by a panel of experts in the fields of thromboembolism, clinical pharmacology, and clinical epidemiology to assure face validity. Interrater agreement for interaction direction and severity, quality of study, and level of causation was assessed using a weighted κ statistic.CONFLICTING EVIDENCEIf ratings differed among articles for the same interacting drug or food, a hierarchy was implemented (type of subject > quality of study > level of causation > severity of clinical outcome). For example, a case report involving a patient was considered to be superior to an RCT using healthy volunteers as subjects. If 2 or more articles had the same subject type, the result of the highest quality study was listed—a patient-based RCT was considered superior to a patient case report. If 2 or more articles with the same subject type and quality of study varied in level of causation and clinical outcome, the clinical outcome associated with the highest level of evidence was listed. For example, the case report describing moderate potentiation of warfarin by celecoxib, with a level II causation ratingoutweighed the level III case report describing a similar interaction.For 2 level III causation patient case reports describing amoxicillin’s effect on warfarin, the report describing major potentiationoutweighed the one describing moderate potentiation.RESULTSA total of 642 citations were identified, of which 205 contained original data on drug or food interactions with warfarin. Of these 205 articles, 181 were retrievable and available for review. The reviewed articles contained 187 separate reports of interactions involving 120 drugs or foods. The weighted κ statistic for the interaction direction and severity rating, level of causation evaluation, and quality of study rating among the reviewers were 0.98, 0.84, and 1.0 respectively. All rating disagreements were resolved by repeated review and consensus.No study met our definition of excellent quality. Thirty-three small RCTs were rated fair or good quality, of which 28 involved healthy subjects and 26 concluded a lack of interaction between warfarin and the drug or food studied. Olestra,vitamin E,clopidogrel,coenzyme Q10/ginkgo biloba 10,and ciprofloxacinwere the only drugs for which patient-based RCTs were conducted, with a “no effect” conclusion for olestra, vitamin E, clopidogrel, and coenzyme Q10/gingko biloba and nonclinical potentiation for ciprofloxacin. Of the reviewed studies, 148 (82%) were rated poor quality and 130 (88%) of these were case reports, of which 125 (96%) were single case reports.Forty-one new reports were rated as level I causation (highly probable) for an interaction, with 14 reporting potentiation (acetaminophen,boldo-fenugreek,ciprofloxacin,citalopram,diltiazem,entacapone,fenofibrate,fish oil,mango,miconazole vaginal suppositories,quilinggao,sertraline,voriconazole,and zileuton), 5 reporting inhibition (etodolac,mercaptopurine,mesalamine,ribavirin,and trazodone), and 22 reporting “no effect” (anastrozole,argatroban,cilostazol,clopidogrel,donepezil hydrochloride,eprosartan,entacapone,gemifloxacin,levetiracetam,losartan,meloxicam,metrifonate,miglitol,modafinil,moexipril,montelukast,nateglinide,nefazodone,olestra,pantoprazole,sevelamer hydrochloride,and vitamin E).For 38 drugs or foods, level II causation (probable) criteria were met, and for the remaining 41 drugs or foods, the evidence was even less conclusive. Only 57 (31%) of the studies ruled out potential confounders, and fewer than 20% of the articles provided rechallenge data, demonstration of a dose response relationship, or a description of a previous exposure in which the patient experienced a similar effect.Of all 184 reviewed reports, 128 (70%) described a potentiation of warfarin’s effect, while inhibition and “no effect” reports each comprised 28 (15%). There were 34 reports of a major interaction—3 case reports of thrombosis associated with trazodone, sulfasalazine, and propofol and 31 case reports describing a major potentiation. These included 8 deaths, 4 of which were due to intracranial bleeding associated with celecoxib, ciprofloxacin, and fluoxetine/diazepam coadministration.Only 2 of all 34 reports were level I, describing inhibition involving mesalamine and trazodone.Several herbal drugs, foods rich in vitamin K, and carbamazepine were reported to decrease warfarin’s effect as were other anti-infective agents, including griseofulvin, rifampin, and penicillinase-resistant penicillins, such as nafcillin, dicloxacillin, and cloxacillin.There were 3 drugs—terbinafine, ritonavir, and influenza vaccine—for which conflicting evidence of an interaction with warfarin was presented.A cumulative summary, combining evaluations from our original reviewwith those of the update is presented in Table 2. Although few interactions met level I causation requirements, the recurrent reports on nonsteroidal anti-inflammatory drugs (NSAIDs),antibiotics (particularly macrolides—azithromycin,erythromycin,and clarithromycin), azoles (fluconazoleand miconazole), amoxicillin, and quinolones (ciprofloxacinand levofloxacin) continue. New alerts regarding the potential for major bleeding when warfarin is taken with cyclooxygenase-2 (COX-2) selective NSAIDsor herbal drugs are raised.Table 3presents a summary of all clinically significant potentiation and inhibition interactions with warfarin, based on drug family and level of causation.Table 2. Drug and Food Interactions With Warfarin by Level of Causation and Direction of Interaction*Level of CausationPotentiationInhibitionNo EffectI (Highly probable)AcetaminophenAlcohol (if concomitant liver disease)†Amiodarone†Anabolic steroids†Boldo-fenugreekCimetidine†Ciprofloxacin‡ (n = 34)Citalopram‡ (n = 12)Clofibrate†Cotrimoxazole†Diltiazem‡ (n = 20)Entacapone‡ (n = 12)Erythromycin†FenofibrateFish oilFluconazole†Isoniazid†MangoMetronidazole†Miconazole oral gel†Miconazole vaginal suppositoriesOmeprazole†Phenylbutazone†Piroxicam†Propafenone†Propranolol†QuilinggaoSertraline‡(n = 12)Sulfinpyrazone (biphasic with later inhibition)†Voriconazole‡ (n = 17)Zileuton‡ (n = 24)BarbituatesCarbamazepine†Chlordiazepoxide†Cholestyramine†Etodolac‡ (N = 18)Griseofulvin†MercaptopurineMesalamineNafcillin†RibavirinRifampin†Sucralfate†TrazodoneHigh vitamin K content foods/enteral feeds†Large amounts of avocado†Alcohol†Anastrozole‡ (N = 16)Antacids†Argatroban‡Atenolol†Bumetadine†Cilostazol‡ (N = 15)Clopidogrel‡ (N = 43)Diflunisal†Donepezil hydrochloride‡ (N = 12)Enoxacin†Eprosartan‡ (N = 18)Famotidine†Felodipine†Fluoxetine†Fondaparinux‡ (N = 12)Gemifloxacin‡ (n = 35)Ketorolac†Levetiracetam‡ (N = 26)Losartan‡ (N = 9)Meloxicam‡ (N = 13)Metoprolol†Metrifonate‡ (N = 14)Miglitol‡ (N = 19)Modafinil‡ (N = 28)Moexipril‡ (N = 10)Montelukast‡ (N = 12)Moricizine†Naproxen†Nateglinide‡ (N = 12)Nefazodone‡ (N = 17)Nizatidine†Olestra‡ (N = 36)Pantoprazole‡ (N = 26)Psyllium†Ranitidine†Sevelamer hydrochloride‡ (N = 14)Vitamin E‡ (N = 25)II (Probable)Acetylsalicylic acid†Amoxicillin/clavulanateAzithromycinCelecoxibChoral hydrate†ClarithromycinDanshenDextropropoxyphene†Disulfiram†Dong quaiFluorouracilFluvastatinFluvoxamineGemcitabineGrapefruit juiceInterferonItraconazole†Levamisole/fluorouracilLevofloxacinLycium barbarum LPC-SPESPaclitaxelParacetemolPhenytoin (biphasic with later inhibition)†Quinidine†RitonavirRopiniroleSimvastatin†Tamoxifen†Tetracycline†TolterodineTramadolTroglitazoneAzathioprineBosentanCandesartan cilexetil‡Chelation therapyDicloxacillin†GinsengInfluenza vaccineMultivitamin supplement containing vitamin KRaloxifene hydrochlorideRitonavirSoy milkAtorvastatinCilomilast‡ (N = 36)Coenzyme Q10/ginkgo biloba‡ (N = 24)Colesevelam hydrochlorideIbuprofen†Influenza vaccine†Ketoconazole†Ketoprofen†LevosimendanIII (Possible)AcarboseAmiodarone-induced toxicosisAmoxicillinAmoxicillin/tranexamic rinseCMF (cyclophosphamide/methotrexate/fluorouracil)ChloramphenicolCranberry juiceCurbicinDanazolDanshen/methyl salicylateDisopyramide†FelbamateGatifloxacinGemfibrozilIndomethacinIfosphamide†Lovastatin†LeflunomideMetolazone†Miconazole topical gelNalidixic acid†Norfloxacin†Ofloxacin†OrlistatPropoxyphene†RofecoxibTopical salicylates†SaquinavirSulindac†TerbinafineTiclopidineTolmetin†TrastuzumabCyclosporine†Etretinate†SulfasalazineSushi containing seaweedTelmisartanTerbinafineUbidicarenoneIV (Highly improbable)BezafibrateCefamandole†Cefazolin†Etoposide/carboplatinFluoxetine/diazepamHeparin†LevamisoleEvonorgestrelMethylprednisoloneNabumetoneQuetiapineSulfisoxazole†mFurosemideGreen teaNafcillin/dicloxacillinPropofolTeicoplaninTobacco†Vancomycin†*Interaction key: major interaction (bold/italics); moderate interaction (bold); minor interaction (italics); nonclinical interaction (regular).†Data from 1994 review.‡Drugs and foods for which evidence is based on fair- to good-quality randomized controlled trials; numbers in parentheses indicate number of subjects in trial.Table 3. Clinically Significant Interactions With Warfarin by Level of Causation and Drug GroupLevel of CausationAnti-infectivesCardiovascular DrugsAnalgesics, Anti-inflammatories and ImmunologicsCNS DrugsPotentiationI (Highly probable)CiprofloxacinCotrimoxazoleErythromycinFluconazoleIsoniazid (600 mg/d)MetronidazoleMiconazole oral gelMiconazole vaginal suppositoriesVoriconazoleAmiodaroneClofibrateDiltiazemFenofibratePropafenonePropranololSulfinpyrazone (biphasic with later inhibition)PhenylbutazonePiroxicamAlcohol (if concomitant liver disease)CitalopramEntacaponeSertralineII (Probable)Amoxicillin/clavulanateAzithromycinClarithromycinItraconazoleLevofloxacinRitonavirTetracyclineAcetylsalicylic acidFluvastatinQuinidineRopiniroleSimvastatinAcetaminophenAcetylsalicylic acidCelecoxibDextropropoxypheneInterferonTramadolDisulfiramChoral hydrateFluvoxaminePhenytoin (biphasic with later inhibition)III (Possible)AmoxicillinAmoxicillin/tranexamic rinseChloramphenicolGatifloxacinMiconazole topical gelNalidixic acidNorfloxacinOfloxacinSaquinavirTerbinafineAmiodarone-induced toxicosisDisopyramideGemfibrozilMetolazoneCelecoxibIndomethacinLeflunomidePropoxypheneRofecoxibSulindacTolmetinTopical salicylatesFelbamateIV (Highly improbable)CefamandoleCefazolinSulfisoxazoleBezafibrateHeparinLevamisoleMethylprednisoloneNabumetoneFluoxetine/diazepamQuetiapineInhibitionI (Highly probable)GriseofulvinNafcillinRibavirinRifampinCholestyramineMesalamineBarbituratesCarbamazepineII (Probable)DicloxacillinRitonavirBosentanAzathioprineChlordiazepoxideIII (Possible)TerbinafineTelmisartanSulfasalazineIV (Highly improbable)CloxacillinNafcillin/dicloxacillinTeicoplaninFurosemidePropofolPotentiationI (Highly probable)CimetidineFish oilMangoOmeprazoleBoldo-fenugreekQuilinggaoAnabolic steroidsZileutonII (Probable)Grapefruit juiceDanshenDong quaiLycium barbarum LPC-SPESFluorouracilGemcitabineLevamisole/fluorouracilPaclitaxelTamoxifenTolterodineIII (Possible)Cranberry juiceOrlistatDanshen/methyl salicylateAcarboseCMF (cyclophosphamide/methotrexate/fluorouracil)CurbicinDanazolIfosphamideTrastuzumabIV (Highly improbable)Etoposide/carboplatinLevonorgestrelInhibitionI (Highly probable)High vitamin K content foods/enteral feedsAvocado (large amounts)MercaptopurineII (Probable)Soy milkSucralfateGinsengChelation therapyInfluenza vaccineMultivitamin supplementRaloxifene hydrochlorideIII (Possible)Sushi containing seaweedCyclosporineEtretinateUbidicarenoneIV (Highly improbable)Green tea Abbreviations: CNS, central nervous system; GI, gastrointestinal.The most commonly cited mechanisms for interactions with warfarin involved stereoselective clearance due to S-enantiomer (ritonavir and cotrimoxazole) or nonstereoselective clearance (simvastatin and terbinafine) or the vitamin K pathway (green tea). However, most of the interactions reported have no documented mechanism.COMMENTThis updated review indicates that the number of reports of interactions between warfarin and drugs or foods is increasing, reaffirming both the anticoagulant’s widespread use and its use with concomitant medications. Although the true mechanisms of drug interactions almost always remain unknown, there are several pharmacokinetic and pharmacodynamic factors that could influence warfarin’s effect. Cholestyramine is thought to reduce the gastrointestinal absorption of warfarin.The more potent warfarin S-isomer is metabolized by cytochrome P-450 (CYP) 2C9. Many of the drugs identified as potentiating warfarin’s effect are known inhibitors of CYP 2C9, including amiodarone, fluconazole, fluvastatin, fluvoxamine, isoniazid, lovastatin, phenylbutazone, and sertraline.Rifampin and secobarbital are both known inducers of CYP 2C9.The R-isomer of warfarin is metabolized by CYP 1A2 and CYP 3A4, and quinolonesinhibit CYP 1A2, and macrolidesinhibit CYP 3A4. The azoles (several reports involving metronidazole, fluconazole, trimethoprim-sulfamethoxazole, miconazole, and voriconazole) are also considered to inhibit CYP 1A2 or CYP 3A4. The pharmacodynamics of warfarin may be influenced by medications that affect either vitamin K or the coagulation factors.Sudden changes in dietary sources of vitamin K such as leafy greens or a supplemented diet followed by a change in warfarin’s effect are relatively easy to understand.However, for several drugs, including cephalosporins, levothyroxine, and clofibrate, their supposed pharmacodynamic interactions with warfarin are very poorly understood.Although understanding a drug’s pharmacology helps predict its potential for interaction with warfarin, the translation of these predictions into clinical reality is far from certain. We also found no evidence that specific factors might identify patient subgroups most at risk of pharmacokinetic drug interactions. Regular monitoring of INR remains the best protection against major harm due to these pharmacokinetic and pharmacodynamic interactions.The most difficult groups of drugs to deal with are those that potentiate bleeding on their own. The risk of bleeding is then greater when taken with warfarin, and INR monitoring is of no help. This is an issue with other anticoagulants (such as heparin), antiplatelet drugs (eg, acetylsalicylic acid, clopidogrel, dipyridamole, sulfinpyrazone, and ticlopidine) and all NSAIDs including COX-2 selective NSAIDs. All of these drugs should be avoided in combination with warfarin unless proven to provide benefit that outweighs the risk of bleeding—for example, for artificial heart valves.Contrary to the early theories of safety of COX-2 selective NSAIDs, we do not consider them safe in combination with warfarin. Both celecoxib (10 cases moderateto major) and rofecoxib (2 cases moderate) are reported to potentiate anticoagulation. Acetaminophen, which is the analgesic of choice for patients using warfarin, has case reportsas well as a case-control studysuggesting moderate potentiation (perhaps based on mild factor VII depletion), although findings from an RCT in healthy volunteers were negative.The paradox noted in our original review continues, in that higher-quality studies describe minor or no interaction, while clinically important potentiation or inhibition interactions all originate from poor-quality reports. The overall quality of the interaction literature remains extremely poor, precluding definitive recommendations regarding the safe coadministration or avoidance of specific drugs and foods in users of warfarin. Case reports may be alarming, but their rarity and the lack of a control group, a denominator of use, or often even basic descriptive details makes it impossible to gauge their true accuracy or rate of harm. Small RCTs of new drugs given with warfarin are increasingly common as a result of demands of regulators. These studies, which are invariably carried out with healthy young male volunteers, are too small to provide any assurance of lack of interaction and are likely not generalizable to the usual warfarin consumer—an elderly person with active medical conditions using several other medications. Only 5 of 34 RCTs evaluated in this review involved sample sizes from 24 to 43 patients.Poor-quality literature is not merely an aggravation to review. Twenty of the interaction reports received a level IV causation rating, implying that the interaction was highly improbable based on the lack of fulfillment of basic causation criteria.The publication of such reports is potentially harmful itself because it may generate unwarranted concern and erroneously influence prescribing. We were surprised to find no analyses of linked, large administrative databases examining drug interactions with warfarin.This review has several limitations. Our literature search did not solicit all unpublished adverse interactions reported to drug manufacturers or governments. However, both Health Canada’s Canadian Adverse Drug Reaction Monitoring Program and Food and Drug Administration’s MedWatch were solicited for cases. We also were unable to review all non-English publications. The handling of conflicting evidence, while sensible, could have led to a mistaken conclusion. Others may not agree with our multidimensional, hierarchical evaluation methods.In the extreme, no drug can be deemed “safe” based on our summary chart because the absence of proof of a severe interaction does not mean proof of absence. Idiosyncratic reactions can always be expected. We therefore continue to recommend careful monitoring of warfarin therapy at the time of introduction of any new medication, herbal product, or food. Herbal products are particularly problematic given the lack of quality control on their contents and the failure of clinicians to ask about their use.How can clinicians use this information? To prescribe safely, there are 3 choices: one is to never prescribe or allow another medicine to be given with warfarin. This is clearly impractical for most patients requiring warfarin. The second is to use an electronic medical record or prescribing system that will evaluate interactions among the patient’s entire profile of therapies.Because these systems are not available to most physicians and are frequently incomplete and sometimes inaccurate, a third approach is required. The third option is to group the majority of offending interacting drugs into easier-to-remember families or therapeutic groups, as we have done in Table 3. We recommend to exercise caution when adding any antibiotic to warfarin therapy, especially for macrolides, quinolones, and “azoles.” Many common cardiovascular drugs, including statins, fibrates, heparin, aspirin, and amiodarone, are problematic. Also, NSAIDs, including COX-2 selective NSAIDs, should be avoided, as should omeprazole, alcohol, chloral hydrate, anabolic steroids, and a wide variety of, if not all, herbal supplements. New oral anticoagulants may soon be available but have not demonstrated superior long-term efficacy, safety, or drug interaction profile compared with warfarin.CONCLUSIONSIn summary, there is an abundance of medications and foods for which an adverse interaction with warfarin, generally potentiation of warfarin’s effect, has been reported. While the drug interaction literature is generally of poor quality, relatively consistent reporting of interactions between warfarin and certain commonly used drugs and drug families (mainly anti-infective agents, lipid-lowering drugs, NSAIDs including COX-2 selective NSAIDs, selective serotonin reuptake inhibitors, amiodarone, omeprazole, fluorouracil, and cimetidine) is cause for concern. In patients who are starting therapy with one of these medicines, consideration should be given to using an alternative medication with less potential for warfarin interactions (eg, rabeprazole instead of omeprazole and acetaminophen instead of NSAIDs). More frequent INR testing during the 2 weeks of the onset or discontinuation of treatment with other medications is advisable. Finally, we recommend the use of more rigorous methods to examine warfarin interactions in patients (eg, RCTs, N of 1 crossover studies, or large health database analyses).Correspondence:Anne M. Holbrook, MD, PharmD, MSc, FRCPC, Division of Clinical Pharmacology, McMaster University, c/o Centre for Evaluation of Medicines, 105 Main St E, Level P1, Hamilton, Ontario, Canada L8N 1G6 (holbrook@mcmaster.ca).Accepted for Publication:December 21, 2004.REFERENCESGWAlbersJEDalenALaupacisWJManningPPetersenDESingerAntithrombotic therapy in atrial fibrillation.Chest2001119(suppl)194S206S11157649PDSteinJSAlpertHIBusseyJEDalenAGGTurpieAntithrombotic therapy in patients with mechanical and biological prosthetic heart valves.Chest2001119(suppl)220S227S[published correction appears in Chest. 2001;120:1044]11157651TMAGHyersRDHullTAMorrisMSamamaVTapsonJGWegAntithrombotic therapy for venous thromboembolic disease.Chest2001119(suppl)176S193S11157648JACairnsPTherouxHDLewisJrMEzekowitzTWMeadeAntithrombotic agents in coronary artery disease.Chest2001119(suppl)228S252S[published correction appears in Chest. 2001;120:1427]11157652JHirshJDalenDRAndersonOral anticoagulants: mechanism of action clinical effectiveness and optimal therapeutic range.Chest2001119(suppl 1)8S21S11157640PSWellsAMHolbrookNRCrowtherJHirshInteractions of warfarin with drugs and food.Ann Intern Med19941216766837944078RJBeythLMQuinnCSLandefeldProspective evaluation of an index for predicting the risk of major bleeding in outpatients treated with warfarin.Am J Med199810591999727814JLFleissStatistical Methods for Rates and Proportions.New York, NY: John Wiley & Sons; 1981:212-225JAStadingMZSkrabalMAFaulknerSeven cases of interaction between warfarin and cyclooxygenase-2 inhibitors.Am J Health Syst Pharm2001582076208011715832TLMersfelderLRStewartWarfarin and celecoxib interaction.Ann Pharmacother20003432532710917378GDWoodTDeebleWarfarin: dangers with antibiotics.Dent Update1993203503538056109NPBeckeyLBKormanDParraEffect of the moderate consumption of olestra in patients receiving long-term warfarin therapy.Pharmacotherapy1999191075107910610014JMKimRHWhiteEffect of vitamin E on the anticoagulant response to warfarin.Am J Cardiol1996775455468629604CLidellLESvedbergPLindellSBandhBJobLWallentinClopidogrel and warfarin: absence of interaction in patients receiving long-term anticoagulant therapy for non-valvular atrial fibrillation.Thromb Haemost20038984284612719782JEngelsenJDNielsenKEHansenEffect of coenzyme Q10 and ginkgo biloba on warfarin dosage in patients on long-term warfarin treatment: a randomized double-blind, placebo-controlled cross-over trial.Ugeskr Laeger20031651868187112772396DSIsraelJStotkaWRockEffect of ciprofloxacin on the pharmacokinetics and pharmacodynamics of warfarin.Clin Infect Dis1996222512568838180MGGebauerKNyfort-HandsenPJHenschkeASGallusWarfarin and acetaminophen interaction.Pharmacotherapy20032310911212523469JLambertJCormierPotential interaction between warfarin and boldo-fenugreek.Pharmacotherapy20012150951211310527MPriskornJSSidhuFLarsenJDDavisAZKhanPERolanInvestigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.Br J Clin Pharmacol1997441992029278211AMStoysichBDLucasSMMohiuddinDEHillemanFurther elucidation of pharmacokinetic interaction between diltiazem and warfarin.Int J Clin Pharmacol Ther19963456608929747JDingemanseCMeyerhoffJSchadrackEffect of the catechol-O-methyltransferase inhibitor entacapone on the steady-state pharmacokinetics and pharmacodynamics of warfarin.Br J Clin Pharmacol20025348549111994054KJAscahGARockPSWellsInteraction between fenofibrate and warfarin.Ann Pharmacother1998327657689681093MSBuckleyADGoffWEKnappFish oil interaction with warfarin.Ann Pharmacother200438505314742793JMonterrey-RodriguezInteraction between warfarin and mango fruit [letter].Ann Pharmacother20023694094112014355DJThirionLAZanettiPotentiation of warfarin's hypoprothrombinemic effect with miconazole vaginal suppositories.Pharmacotherapy200020989910641982ALNWongTYKChanInteraction between warfarin and the herbal product quilinggao.Ann Pharmacother20033783683812014354GApseloffKDWilnerNGerberLMTremaineEffect of sertraline on protein binding of warfarin.Clin Pharmacokinet199732(suppl 1)37429068934LPurkinsNWoodDKleinermansDNicholsVoriconazole potentiates warfarin-induced prothrombin time prolongation.Br J Clin Pharmacol200356242914616410WMAwniZHusseinGRGrannemanKJPattersonLMDubeJHCavanaughPharmacodynamic and stereoselective pharmacokinetic interactions between zileuton and warfarin in humans.Clin Pharmacokinet199529(suppl 2)67768620673JCErmerDRHicksSCWheelerMKramlWJJuskoConcomitant etodolac affects neither the unbound clearance nor the pharmacologic effect of warfarin.Clin Pharmacol Ther1994553053168143396LAMartinSDMehtaDiminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy.Pharmacotherapy20032326026412587816MAMarinellaMesalamine and warfarin therapy resulting in decreased warfarin effect.Ann Pharmacother1998328418429681104SSchulmanInhibition of warfarin activity by ribavirin.Ann Pharmacother200236727411816263NLSmallKAGiamonnaInteraction between warfarin and trazodone.Ann Pharmacother20003473473610860134RAYatesJWongMSeiberlingMMerzWMarzMNauckThe effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers.Br J Clin Pharmacol20015142943511422000PMBrownMJHurstingLack of pharmacokinetic interactions between argatroban and warfarin.Am J Health Syst Pharm2002592078208312434720SMallikaarjunSLBramerEffect of cilostazol on the pharmacokinetics and pharmacodynamics of warfarin.Clin Pharmacokinet199937(suppl 2)798610702890PJTiseoKFoleyLTFriedhoffThe effect of multiple doses of donepezil HCl on the pharmacokinetic and pharmacodynamic profile of warfarin.Br J Clin Pharmacol199846(suppl 1)45509839766DJKazieradDEMartinBIlsonEprosartan does not affect the pharmacodynamics of warfarin.J Clin Pharmacol1998386496539702851RAFaaijJBurggraafRCSchoemakerRGMvan AmsterdamAFCohenAbsence of an interaction between the synthetic pentasaccharide fondaparinux and oral warfarin.Br J Clin Pharmacol20025430430812236851MDavyNBirdKLRostHFuderLack of effect of gemifloxacin on the steady-state pharmacodynamics of warfarin in healthy volunteers.Chemotherapy19994549149510567780IRagueneau-MajlessiRHLevyCMeyerhoffLack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin.Epilepsy Res200147556311673021ANKongLTomaskoSAWaldmanLosartan does not affect the pharmacokinetics and pharmacodynamics of warfarin.J Clin Pharmacol199535100810158568008DTurckCASuGHeinzelUBuschEBluhmkiJHoffmannLack of interaction between meloxicam and warfarin in healthy volunteers.Eur J Clin Pharmacol1997514214259049585RHeinigNKitchinPRolanDisposition of a single dose of warfarin in healthy individuals after pretreatment with metrifonate.Clin Drug Invest199918151159RSchallFOMullerHKHundtLDuursemaGGroenewoudMVMiddleStudy of the effect of miglitol on the pharmacokinetics and pharmacodynamics of warfarin in healthy males.Arzneimittelforschung19964641468821516PRobertsonJrETHellriegelSAroraMNelsonEffect of modafinil at steady state on the single-dose pharmacokinetic profile of warfarin in healthy volunteers.J Clin Pharmacol20024220521411831544AVan HeckenRVerbesseltMDepreMoexipril does not alter the pharmacokinetics or pharmacodynamics of warfarin.Eur J Clin Pharmacol1993452912938276058AVan HeckenMDepreRVerbesseltEffect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.J Clin Pharmacol19993949550010234597DMAndersonSShelleyNCrickMBuraglioNo effect of the novel antidiabetic agent nateglinide on the pharmacokinetics and anticoagulant properties of warfarin in healthy volunteers.J Clin Pharmacol2002421358136512463731DESalazarRCDockensRLMilbrathPharmacokinetic and pharmacodynamic evaluation of warfarin and nefazodone coadministration in healthy subjects.J Clin Pharmacol1995357307387560254LDuursemaFOMullerRSchallLack of effect of pantoprazole on the pharmacodynamics and pharmacokinetics of warfarin.Br J Clin Pharmacol1995397007037654493SBurkeNAminCIncertiMPloneNWatsonSevelamer hydrochloride a nonabsorbed phosphate-binding polymer does not interfere with digoxin or warfarin pharmacokinetics.J Clin Pharmacol20014119319811210401DCByrdSEGaskinsAMParrishLBFreemanWarfarin and ciprofloxacin interaction: case report and controversy.J Am Board Fam Pract19991248648810612367MMcMorranIMorawieckaCelecoxib (Celebrex): 1 year later.CMAJ200016210441046, 1048-105010763409LADentMWOrrockWarfarin-fluoxetine and diazepam-fluoxetine interaction.Pharmacotherapy1997171701729017779MGuerretPFrancheteauMHuberEvaluation of effects of terbinafine on single oral dose pharmacokinetics and anticoagulant actions of warfarin in healthy volunteers.Pharmacotherapy1997177677739250555JAWarwickRJCorrallSerious interaction between warfarin and oral terbinafine.BMJ19983164409492670AKGuptaGSRossInteraction between terbinafine and warfarin.Dermatology19981962662679568423GNewshanPTsangRitonavir and warfarin interaction.AIDS1999131788178910509586DPoliLChiarugiMCapanniNeed of more frequent international normalized ratio monitoring in elderly patients on long-term anticoagulant therapy after influenza vaccination.Blood Coagul Fibrinolysis20021329730012032394BALipskyREPecoraroNJRobenPde BlaquiereCJDelaneyInfluenza vaccination and warfarin anticoagulation.Ann Intern Med19841008358376721299PKramerMTsuruCECookCJMcClainJLHoltzmanEffect of influenza vaccine on warfarin anticoagulation.Clin Pharmacol Ther1984354164186697649LDuursemaFOMullerHKHundtADHeynsBHMeyerHGLuusModel to detect warfarin-drug interactions in man.Drug Investig19924395402LDHeimarkLWienkersKKunzeThe mechanism of the interaction between amiodarone and warfarin in humans.Clin Pharmacol Ther1992513984071563209SAlmogNShafranHHalkinMechanism of warfarin potentiation by amiodarone: dose and concentration-dependent inhibition of warfarin elimination.Eur J Clin Pharmacol1985282572614007030RAO'ReillyWFTragerAERettieDAGoulartInteraction of amiodarone with racemic warfarin and its separated enantiomorphs in humans.Clin Pharmacol Ther1987422902943621782KPyoralaGMyllylaMKekkiMetabolism of warfarin during methandrostenolone treatment.Ann Med Exp Biol Fenn19654395975317992SMLorentzRTWeibertPotentiation of warfarin anticoagulation by topical testosterone ointment.Clin Pharm198543323344006400SToonKJHopkinsFMGarstangMRowlandComparative effects of ranitidine and cimetidine on the pharmacokinetics and pharmacodynamics of warfarin in man.Eur J Clin Pharmacol1987321651723582481RAO'ReillyComparative interaction of cimetidine and ranitidine with racemic warfarin in man.Arch Intern Med19841449899916324710WRBellKCAndersonDANoeBASilverReduction in the plasma clearance rate of warfarin induced by cimetidine.Arch Intern Med1986146232523283778066MJSerlinRGSibeonSMossmanCimetidine: interaction with oral anticoagulants in man.Lancet1979231731989387MJSaxWCRandolphKEPeaceEffect of two cimetidine regimens on prothrombin time and warfarin pharmacokinetics during long-term warfarin therapy.Clin Pharm19876492495[published correction appears in Clin Pharm. 1988;7:269]3690995BAHuntMJSaxSChretienWOFrankAJBravermanStereoselective alterations in the pharmacokinetics of warfarin enantiomers with two cimetidine dose regimens.Pharmacotherapy19899184RAO'ReillyMASahudAJRobinsonStudies on the interaction of warfarin and clofibrate in man.Thromb Diath Haemorrh1972273093184340370RAO'ReillyCHMotleyRacemic warfarin and trimethoprim-sulfamethoxazole interaction in humans.Ann Intern Med1979913436464451RTWeibertSMLorentzRJTownsendCECookMRKlauberPIJaggerEffect of erythromycin in patients receiving long-term warfarin therapy.Clin Pharm198982102142706893DBlackJEvansTSeatonBGidalNMcDonnellKKunzeEvaluation of the effect of fluconazole on the stereoselective metabolism of warfarin [abstract].Clin Pharmacol Ther199251piii-52ARRosenthalTHSelfEDBakerRALindenInteraction of isoniazid and warfarin.JAMA19772382177578833RAO'ReillyThe stereoselective interaction of warfarin and metronidazole in man.N Engl J Med1976295354357934223RAO'ReillyDAGoulartKLKunzeMechanisms of the stereoselective interaction between miconazole and racemic warfarin in human subjects.Clin Pharmacol Ther1992516566671611805TSutfinKBalmerHBostromSErikssonPHoglundOPaulsenStereoselective interaction of omeprazole with warfarin in healthy men.Ther Drug Monit1989111761842718223PMAggelerRAO'ReillyLLeongPEKowitzPotentiation of anticoagulant effect of warfarin by phenylbutazone.N Engl J Med19672764965016018280RAO'ReillyWFTragerCHMotleyWHowaldStereoselective interaction of phenylbutazone with [12C/13C] warfarin pseudoracemates in man.J Clin Invest1980657467537354137RSRhodesPJRhodesCKleinCDSintekA warfarin-piroxicam drug interaction.Drug Intell Clin Pharm1985195565584028961REKatesYGYeeEBKirstenInteraction between warfarin and propafenone in healthy volunteer subjects.Clin Pharmacol Ther1987423053113621785AKScottBKParkAMBreckenridgeInteraction between warfarin and propranolol.Br J Clin Pharmacol198417(suppl 1)86S6743477NDBaxMSLennardGTTuckerThe effect of beta-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin.Br J Clin Pharmacol198417(suppl 1)85S6146343GGNenciGAgnelliMBerrettiniBiphasic sulphinpyrazone-warfarin interaction.Br Med J (Clin Res Ed)1981282136113626786498RAO'ReillyStereoselective interaction of sulfinpyrazone with racemic warfarin and its separated enantiomorphs in man.Circulation1982652022077053283SToonLKLowMGibaldiThe warfarin-sulfinpyrazone interaction: stereochemical considerations.Clin Pharmacol Ther19863915243943265RAO'ReillyWFTragerCHMotleyWHowaldInteraction of secobarbital with warfarin pseudoracemates.Clin Pharmacol Ther1980281871957398186MOrmeABreckenridgeEnantiomers of warfarin and phenobarbital.N Engl J Med197629514821483995149JMHansenKSiersboek-NielsenLSkovstedCarbamazepine-induced acceleration of diphenylhydantoin and warfarin metabolism in man.Clin Pharmacol Ther1971125395435567804ABreckenridgeMOrmeClinical implications of enzyme induction.Ann N Y Acad Sci19711794214305285387DSRobinsonDMBenjaminJJMcCormackInteraction of warfarin and nonsystemic gastrointestinal drugs.Clin Pharmacol Ther1971124914955567801EJahnchenTMeinertzHJGilfrichFKerstingUGrothEnhanced elimination of warfarin during treatment with cholestyramine.Br J Clin Pharmacol19785437440656283KOkinoRTWeibertWarfarin-griseofulvin interaction.Drug Intell Clin Pharm1986202912933698827SICullenPCatalanoGriseofulvin-warfarin antagonism.JAMA19671995825836071326GDQureshiTPReindersGJSomoriHJEvansWarfarin resistance with nafcillin therapy.Ann Intern Med19841005275296703546RAO'ReillyInteraction of sodium warfarin and rifampin: studies in man.Ann Intern Med1974813373404852505LDHeimarkMGibaldiWFTragerRAO'ReillyDAGoulartThe mechanism of the warfarin-rifampin drug interaction in humans.Clin Pharmacol Ther1987423883943665337DMungallRLTalbertCPhillipsDJaffeTMLuddenSucralfate and warfarin [letter].Ann Intern Med1983985576687662RLTalbertCDalmady-IsraelHIBusseyMHCrawfordTMLuddenEffect of sucralfate on plasma warfarin concentration in patients requiring chronic warfarin therapy.Drug Intell Clin Pharm19851959GDQureshiTPReindersJJSwintMBSlateAcquired warfarin resistance and weight-reducing diet.Arch Intern Med19811415075097212893MDParrKERecordGLGriffithJVZeokEPToddEffect of enteral nutrition on warfarin therapy.Clin Pharm198212742766821036DBlicksteinMShaklaiAInbalWarfarin antagonism by avocado [letter].Lancet19913379149151672990RAO'ReillyLack of effect of fortified wine ingested during fasting and anticoagulant therapy.Arch Intern Med19811414584597212888RAO'ReillyLack of effect of mealtime wine on the hypoprothrombinemia of oral anticoagulants.Am J Med Sci1979277189194463946HNipperSKirbyFLIberEffect of bumetanide on the serum disappearance of warfarin sodium.J Clin Pharmacol1981216546567338576MJSerlinSMossmanRGSibeonKFTemperoAMBreckenridgeInteraction between diflunisal and warfarin.Clin Pharmacol Ther1980284934987408409SToonKJHopkinsFMGarstangLAaronsASedmanMRowlandEnoxacin-warfarin interaction: pharmacokinetic and stereochemical aspects.Clin Pharmacol Ther19874233413474093IDe LepeleireAVan HeckenRVerbesseltLack of interaction between famotidine and warfarin.Int J Clin Pharmacol Res1990101671712228341MGrindMMurphySWarringtonJAbergMethod for studying drug-warfarin interactions.Clin Pharmacol Ther1993543813878222480HRoweRCarmichaelLLembergerThe effect of fluoxetine on warfarin metabolism in the rat and man.Life Sci197823807812309056SToonBLHoltFGMullinsRBullinghamLAaronsMRowlandInvestigations into the potential effects of multiple dose ketorolac on the pharmacokinetics and pharmacodynamics of racemic warfarin.Br J Clin Pharmacol1990307437502271374IHBenedekSYKingRJPowellAMAgraWLScharyHJPieniaszekJrEffect of moricizine on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.J Clin Pharmacol1992325585631634644AJainFGMcMahonJTSlatteryGLevyEffect of naproxen on the steady-state serum concentration and anticoagulant activity of warfarin.Clin Pharmacol Ther1979256166758244ACournotIBerlinJCSallordESinglasLack of interaction between nizatidine and warfarin during chronic administration.J Clin Pharmacol198828112011222907521MJSerlinRGSibeonAMBreckenridgeLack of effect of ranitidine on warfarin action.Br J Clin Pharmacol1981127917946122462MOrmeABreckenridgePCookWarfarin and distalgesic interaction.BMJ197612001247776LDavydovMYermolnikLJCuniWarfarin and amoxicillin/clavulanate drug interaction.Ann Pharmacother20033736737012639164DRFosterNLMilanPotential interaction between azithromycin and warfarin.Pharmacotherapy19991990290810417043JAUdallWarfarin interactions with chloral hydrate and glutethimide.Curr Ther Res Clin Exp1975176774806430MByersClarithromycin-warfarin interaction resulting in an elevated INR.Can J Hosp Pharm199750285287MBIzzatAPYimMHEl ZufariA taste of Chinese medicine.Ann Thorac Surg1998669419429768962RSmithDPruddenCHawkesPropoxyphene and warfarin interaction [letter].Drug Intell Clin Pharm1984188226489165RAO'ReillyDynamic interaction between disulfiram and separated enantiomorphs of racemic warfarin.Clin Pharmacol Ther1981293323367471603RLPageJDLawrencePotentiation of warfarin by dong quai.Pharmacotherapy19991987087610417036JCarabinoFWangInternational normalized ratio fluctuation with warfarin-fluorouracil therapy [letter].Am J Health Syst Pharm20025987512004471LETrilliCLKelleySLAspinallBAKronerPotential interaction between warfarin and fluvastatin.Ann Pharmacother199630139914028968451KKLimkeARSheltonESElliottFluvoxamine interaction with warfarin.Ann Pharmacother2002361890189212452751SAKinikarJMKolesarIdentification of a gemcitabine-warfarin interaction.Pharmacotherapy1999191331133310555940WRBartleGrapefruit juice might still be factor in warfarin response [letter].Am J Health Syst Pharm19995667610423213YAdachiYYokoyamaTNannoTYamamotoPotentiation of warfarin by interferon.BMJ19953112927543311JYehSCSooCSummertonCRichardsonPotentiation of action of warfarin by itraconazole.BMJ19903016692171705MAScarfeMKIsraelPossible drug interaction between warfarin and combination of levamisole and fluorouracil.Ann Pharmacother1994284644678038468SLRavnanCLockeLevofloxacin and warfarin interaction.Pharmacotherapy20012188488511444586AYLamGWElmerMAMohutskyPossible interaction between warfarin and Lycium barbarum L.Ann Pharmacother2001351199120111675844NBDavisLNahlikNJVogelzangDoes PC-SPES interact with warfarin?J Urol2002167179311912419METhompsonMSHighleyInteraction between paclitaxel and warfarin [letter].Ann Oncol20031450012598362DAFitzmauriceJAMurrayPotentiation of the anticoagulant effect of warfarin.Postgrad Med J1997734394409338037MLevineISheppardBiphasic interaction of phenytoin with warfarin.Clin Pharm198432002036723231JKoch-WeserQuinidine-induced hypoprothrombinemic hemorrhage in patients on chronic warfarin therapy.Ann Intern Med1968685115175643674JDBairTFOppeltWarfarin and ropinirole interaction.Ann Pharmacother2001351202120411675845AGawDWosornuSimvastatin during warfarin therapy in hyperlipoproteinaemia [letter].Lancet19923409799801357387JCLinMKItoSNStolleyAPMorrealeDBMarcusThe effect of converting from pravastatin to simvastatin on the pharmacodynamics of warfarin.J Clin Pharmacol19993986909987704RLodwickBMcConkeyAMBrownLife threatening interaction between tamoxifen and warfarin.Br Med J (Clin Res Ed)198729511413120919LKWestfallAn unrecognized cause of warfarin resistance [letter].Drug Intell Clin Pharm1981151317274023EADanosApparent potentiation of warfarin activity by tetracycline.Clin Pharm1992118068081521405VJColucciMPRiveyTolterodine-warfarin drug interaction.Ann Pharmacother1999331173117610573314JRSabbePJSimsMHSimsTramadol-warfarin interaction.Pharmacotherapy1998188718739692666MLScherNHHuntingtonJAVitilloPotential interaction between tramadol and warfarin [letter].Ann Pharmacother1997316466479161668BKPlowmanAPMorrealePossible troglitazone-warfarin interaction [letter].Am J Health Syst Pharm19985510719606460MRotenbergYLevyYShoenfeldSAlmogDEzraEffect of azathioprine on the anticoagulant activity of warfarin.Ann Pharmacother20003412012210669196LMMurpheyEHHoodBosentan and warfarin interaction.Ann Pharmacother2003371028103112841813JHJonkmanJJvan LierPNvan HeiningenRLinsRSennewaldAHogemannPharmacokinetic drug interaction studies with candesartan cilexetil.J Hum Hypertens199711(suppl 2)S31S359331003HBGrebePJGregoryInhibition of warfarin anticoagulation associated with chelation therapy.Pharmacotherapy2002221067106912173793PMKrstenanskyWNJonesHSGarewalEffect of dicloxacillin sodium on the hypoprothrombinemic response to warfarin sodium.Clin Pharm198768048063505843ATMaillouxBEGidalCASorknessPotential interaction between warfarin and dicloxacillin.Ann Pharmacother199630140214078968452MFRosadoThrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product.Cardiology20039911112711887DKurnikALubetskyRLoebsteinSAlmogHHalkinMultivitamin supplements may affect warfarin anticoagulation in susceptible patients.Ann Pharmacother2003371603160614565795JWMillerASkerjanecMPKnadlerAGhoshSRBAllerheiligenDivergent effects of raloxifene HCl on the pharmacokinetics and pharmacodynamics of warfarin.Pharm Res2001181024102811496940KRKnoellTMYoungESCousinsPotential interaction involving warfarin and ritonavir.Ann Pharmacother199832129913029876810JACambria-KielyEffect of soy milk on warfarin efficacy.Ann Pharmacother2002361893189612452752RSternRAbelGLGibsonJBessererAtorvastatin does not alter the anticoagulant activity of warfarin.J Clin Pharmacol199737106210649506000JKellyRDMurdochDJClarkDMWebberHFuderWarfarin pharmacodynamics unaffected by cilomilast.Ann Pharmacother2001351535153911793614JMDonovanDStypinskiMRStilesTAOlsonSKBurkeDrug interactions with colesevelam hydrochloride: a novel potent lipid-lowering agent.Cardiovasc Drugs Ther20001468169011300370SSchulmanKHenrikssonInteraction of ibuprofen and warfarin on primary haemostasis.Br J Rheumatol19892846492783873CBrassJNGalgianiTFBlaschkeRDefeliceRAO'ReillyDAStevensDisposition of ketoconazole an oral antifungal in humans.Antimicrob Agents Chemother1982211511586282204CMieszczakKWintherLack of interaction of ketoprofen with warfarin.Eur J Clin Pharmacol1993442052068453969SAntilaAJarvinenTHonkanenLLehtonenPharmacokinetic and pharmacodynamic interactions between the novel calcium sensitiser levosimendan and warfarin.Eur J Clin Pharmacol20005670571011214780APMorrealeKJanetzkyProbable interaction of warfarin and acarbose.Am J Health Syst Pharm199754155115529217947KAWoeberIWarnerPotentiation of warfarin sodium by amiodarone-induced thyrotoxicosis.West J Med199917049519926737TBandrowskyAAVoronoTJBorrisHWMarcantoniAmoxicillin-related postextraction bleeding in an anticoagulated patient with tranexamic acid rinses.Oral Surg Oral Med Oral Pathol Oral Radiol Endod1996826106128974131PMalacarneAMaestriPossible interactions between antiblastic agents and warfarin inducing prothrombin time abnormalities [letter].Recenti Prog Med1996871358650435RLeoneEGhiottoAConfortiGVeloPotential interaction between warfarin and ocular chloramphenicol [letter].Ann Pharmacother1999331149972397RSuvarnaMPirmohamedLHendersonPossible interaction between warfarin and cranberry juice.BMJ2003327145414684645QYueKJanssonHerbal drug curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component [letter].J Am Geriatr Soc20014983811454132CDBoothDrug interaction between danazol and warfarin.Pharm J1993250439440LSTamTYChanWKLeungJACritchleyWarfarin interactions with Chinese traditional medicines: danshen and methyl salicylate medicated oil [letter].Aust N Z J Med1995252587487701CSylvenPAndersonEvidence that disopyramide does not interact with warfarin.Br Med J (Clin Res Ed)198328611816404381EHaworthAKBurroughsDisopyramide and warfarin interaction.BMJ19772866867922330KATisdelDSIsraelKWKolbWarfarin-felbamate interaction: first report [letter].Ann Pharmacother1994288057919574RJArtymowiczBJCinoJGRossiJLWalkerSMoorePossible interaction between gatifloxacin and warfarin.Am J Health Syst Pharm2002591205120612073864JPRindoneHCKengGemfibrozil-warfarin drug interaction resulting in profound hypoprothrombinemia.Chest19981146416429726762TYChanSFLuiSYChungSLukJACritchleyAdverse interaction between warfarin and indomethacin.Drug Saf1994102672697880236GHallMJLindMHuangIntravenous infusions of ifosfamide/mesna and perturbation of warfarin anticoagulant control.Postgrad Med J1990668608612129174SAhmadLovastatin: warfarin interaction.Arch Intern Med199015024072241455VLimIPandeLeflunomide can potentiate the anticoagulant effect of warfarin.BMJ2002325133312468482VFTrewinA probable interaction between warfarin and metolazone.Pharm J198818781782JEvansDSOrmeMLSedgwickGRYoungsTreating oral candidiasis: potentially fatal [letter].Br Dent J19971824529231515JLeorDLevartowskyCSharonInteraction between nalidixic acid and warfarin [letter].Ann Intern Med19871076013631807TLinvilleDMataninNorfloxacin and warfarin.Ann Intern Med19891107517522930115JLeorSMatetzkiOfloxacin and warfarin [letter].Ann Intern Med19881097613190063AMBaciewiczBHAsharTWLockeInteraction of ofloxacin and warfarin [letter].Ann Intern Med199311912238239258RSMacWalterHWFraserKMArmstrongOrlistat enhances warfarin effect.Ann Pharmacother20033751051212659605FLittletonWarfarin and topical salicylates [letter].JAMA199026328882338749WHChowKLCheungHMLingTSeePotentiation of warfarin anticoagulation by topical methylsalicylate ointment.J R Soc Med1989825015022778785MRDarlingtonHypoprothrombinemia during concomitant therapy with warfarin and saquinavir [letter].Ann Pharmacother1997316479161669SACarterPotential effect of sulindac on response of prothrombin-time to oral anticoagulants.Lancet1979269869990792JRRossLBeeleySulindac prothrombin time and anticoagulants [letter].Lancet19792107591811BEGidalCASorknessKAMcGillRLarsonRRLevineEvaluation of a potential enantioselective interaction between ticlopidine and warfarin in chronically anticoagulated patients.Ther Drug Monit19951733387725374JFKorenDLCochranRLJanesTolmetin-warfarin interaction.Am J Med198782127812803605152MJNissenblattGIKarpBleeding risk with trastuzumab (Herceptin) treatment.JAMA19992822299230110612314DSSnyderInteraction between cyclosporine and warfarin [letter].Ann Intern Med19881083113124684LSOstlereJALangtrySJonesRCStaughtonReduced therapeutic effect of warfarin caused by etretinate [letter].Br J Dermatol19911245052039731AMTeefyJEMartinMJKovacsWarfarin resistance due to sulfasalazine.Ann Pharmacother2000341265126811098339WRBartlePMadorinFGuylaineSeaweed, vitamin K, and warfarin [letter].Am J Health Syst Pharm200158230011763808JStangierCASuMGHendriksSteady-state pharmacodynamics and pharmacokinetics of warfarin in the presence and absence of telmisartan in healthy male volunteers.J Clin Pharmacol2000401331133711185631OSpigsetReduced effect of warfarin caused by ubidecarenone [letter].Lancet1994344137213737968059TRBeringerWarfarin potentiation with bezafibrate.Postgrad Med J1997736576589497982DMAngaranVCDiasKVAromThe comparative influence of prophylactic antibiotics on the prothrombin response to warfarin in the postoperative prosthetic cardiac valve patient: cefamandole cefazolin vancomycin.Ann Surg19872061551613300580ATLeNKHassonBLLumEnhancement of warfarin response in a patient receiving etoposide and carboplatin chemotherapy.Ann Pharmacother199731100610089296241PThomasAFennertyGBlackhouseOral anticoagulant during treatment with heparin.Br Med J (Clin Res Ed)19842881916419853TWWehbeJAWarthA case of bleeding requiring hospitalization that was likely caused by an interaction between warfarin and levamisole.Clin Pharmacol Ther1996593603628653999JEllisonApparent interaction between warfarin and levonorgestrel used for emergency contraception.BMJ2000321138211099283MKaufmanTreatment of multiple sclerosis with high-dose corticosteroids may prolong the prothrombin time to dangerous levels in patients taking warfarin.Mult Scler199732482499372508VCDennisBKThomasJEHanlonPotentiation of oral anticoagulation and hemarthrosis associated with nabumetone.Pharmacotherapy20002023423910678303TRogersJde LeonDAtcherPossible interaction between warfarin and quetiapine [letter].J Clin Psychopharmacol19991938238310440472LJSiorisRTWeibertPRPentelPotentiation of warfarin anticoagulation by sulfisoxazole.Arch Intern Med19801405465477362390OMIbrahimAAllamWarfarin resistance in a patient with prosthetic valve endocarditis treated with cloxacillin.Saudi Pharm J199645659SCLaizureLMadlockMCyrTSelfDecreased hypoprothrombinemic effect of warfarin associated with furosemide.Ther Drug Monit1997193613639200780JRTaylorVMWiltProbable antagonism of warfarin by green tea.Ann Pharmacother19993342642810332534SMSetterKLawlessKAHunterNeed for continuity of care in patients receiving warfarin and nafcillin/dicloxacillin.Hosp Pharm19963112691271RMacLarenBAWachsmanDKSwiftDAKuhlWarfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature.Pharmacotherapy199717133113379399621FGAgostaNLLiberatoFChiofaloWarfarin resistance induced by teicoplanin [letter].Haematologica1997826376389407741JRMayJTDiPiroJFSisleyDrug interactions in surgical patients.Am J Surg19871533273352881497GMGabbFatal outcome of interaction between warfarin and a non-steroidal anti-inflammatory drug [letter].Med J Aust19961647007018657040AMBaciewiczJJMenkeJABokarEBBaudFluconazole-warfarin interaction [letter].Ann Pharmacother19942811117803894KKHaaseCHRojas-FernandezLLaneDAFrankPotential interaction between celecoxib and warfarin.Ann Pharmacother20003466666710852097KJanetzkyAPMorrealeProbable interaction between warfarin and ginseng.Am J Health Syst Pharm1997546926939075501AMHolbrookPSWellsNRCrowtherPharmacokinetics and drug interactions with warfarin.In: Poller L, Hirsh J, eds. Oral Anticoagulants. Dunton Green, England: Hodder and Stoughton; 1996Indiana University Department of Medicine Web siteCytochrome P450 drug interaction table.Available at: http://medicine.iupui.edu/flockhart/table.htm.Accessed July 15, 2004RAO'ReillyStereoselective interaction of trimethoprim-sulfamethoxazole with the separated enantiomorphs of racemic warfarin in man.N Engl J Med198030233357350395JHirshJAnsellJAnsellJLHalperinAmerican Heart Association/American College of Cardiology foundation guide to warfarin therapy.Circulation20031071692171112668507JEHarrisInteraction of dietary factors with oral anticoagulants: review and applications.J Am Diet Assoc1995955805847722194RAO'ReillyDRytand“Resistance” to warfarin due to unrecognized vitamin K supplementation [letter].N Engl J Med19803031601617383081FMPedersenOHamburgKHessLOvesenThe effect of dietary vitamin K on warfarin-induced anticoagulants.J Intern Med19912295175202045759JCOwensJBNeelyWROwenEffect of sodium dextrothyroxine in patients receiving anticoagulation.N Engl J Med1962266767914482918AMAntlitzJAMeadJrMATolentinoPotentiation of oral anticoagulant therapy by acetaminophen.Curr Ther Res Clin Exp1968105015074971464EMHylekHHeimanSJSkatesMASheehanDESingerAcetaminophen and other risk factors for excessive warfarin anticoagulation.JAMA19982796576629496982DKwanWRBartleSEWalkerThe effects of acetaminophen on pharmacokinetics and pharmacodynamics of warfarin.J Clin Pharmacol19993968759987702LMGianniWBDreitleinSome popular OTC herbals can interact with anticoagulant therapy.US Pharm19982380, 8384, 86BSJoshiPNKaulAlternative medicine: herbal drugs and their critical appraisal—part I.Prog Drug Res20015617611417111AMHolbrookVJanjusevicKKeshavjeeHKLeeMeasuring quality of prescribing: where does the information reside? [abstract].Can J Clin Pharmacol2002940AMHolbrookKKeshavjeeCHGoldsmithJTuckerLParkAdvancing the measurement of quality of care using electronic medical records.Proc Towards Electron Patient Rec19991848855

Journal

JAMA Internal Medicine – American Medical Association

Published: May 23, 2005

There are no references for this article.